[(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid (roxadustat) for the treatment of chemotherapy-induced anemia (CIA)

Roxadustat addresses the limitations of current anemia treatments by enhancing erythropoiesis and iron availability, providing effective hemoglobin elevation in chemotherapy-induced anemia patients with improved safety and efficacy compared to traditional agents.

WO2024238207A1PCT designated stage expired Publication Date: 2024-11-21FIBROGEN INC +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/028163
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-11-03
Filing Date
2024-05-07
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current management options for chemotherapy-induced anemia, such as erythropoietin stimulating agents and red blood cell transfusions, have limitations, including association with venous thromboembolism and insufficient response rates, and iron supplementation is contraindicated in cytotoxic chemotherapy patients, highlighting the need for alternative treatments.

Method used

The use of roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, which increases endogenous erythropoietin production, improves iron availability, and reduces hepcidin, thereby promoting coordinated erythropoiesis, effectively treating anemia in patients receiving myelosuppressive chemotherapy without the need for supplemental intravenous iron.

Benefits of technology

Roxadustat significantly increases red blood cell production, maintains plasma erythropoietin levels within normal ranges, and is effective in patients with chemotherapy-induced anemia, offering a more effective treatment option compared to traditional erythropoiesis-stimulating agents by achieving higher hemoglobin increases in a shorter timeframe.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024028163_21112024_PF_FP_ABST
    Figure US2024028163_21112024_PF_FP_ABST
Patent Text Reader

Abstract

The present application relates to methods of treating chemotherapy-induced anemia in a subject receiving multi-cycle platinum or non-platinum myelosuppressive chemotherapy for a non-myeloid malignancy, wherein the subject has a hemoglobin level ≤100 g / L prior to treatment and the subject's blood hemoglobin level decreased at least 10 g / L after the initiation of chemotherapy, comprising administering roxadustat to the subject.
Need to check novelty before this filing date? Find Prior Art

Description

[(4-HYDROXY-1-METHYL-7-PHENOXYISOQUINOLINE-3- CARBONYL)AMINO]ACETIC ACID (ROXADUSTAT) FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED ANEMIA (CIA)CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] The present application claims benefit of priority to U.S. Provisional Application No. 63 / 502,873, filed May 17, 2023, and U.S. Provisional Application No. 63 / 516,705, filed July 31, 2023, the contents of which are hereby incorporated by reference in their entirety. The Application also claims benefit of priority to Chinese Patent Application No.202311457714.0, filed November 3, 2023, the contents of which is hereby incorporated by reference in its entirety.BACKGROUND

[0002] Chemotherapy-induced anemia (CIA) results from reduction in red blood cell (RBC) production by the bone marrow due to myelosuppression by chemotherapeutic agents, thereby reducing hemoglobin (Hb) level. While some chemotherapeutic agents, such as cisplatin and ifosfamide, may also produce nephrotoxicity leading to reduced endogenous erythropoietin production, most CIA patients have active kidneys that make erythropoietin in response to the reduction in RBCs caused by chemotherapeutic agents. These patients often present with already high circulating levels of serum erythropoietin even though they are anemic suggesting that increasing endogenous erythropoietin production alone is often insufficient to treat CIA. Thus, unlike the erythropoietin-deficiency anemia produced by CKD, chemotherapy-induced anemia is primarily due to defective erythroid progenitor proliferation in the bone marrow.

[0003] The prevalence of CIA amongst patients with solid tumors receiving myelosuppressive chemotherapy has been reported to be 86-98%, with a higher prevalence among those with advanced disease and those receiving multiple treatment cycles. (Xu et al. (2016) Clin Epidemiol 8:61-71). CIA is a significant health burden and is associated with increased morbidity, mortality, and healthcare costs, as well as a decreased quality of life. (Xu et al., supra,' Busti et al. (2018) Pharmaceuticals (Basel, Switzerland) 11:94). Current management options for CIA include erythropoietin stimulating agents (ESAs), red blood cell (RBC) transfusions, and iron supplementation. (Escobar et al. (2021) Clin Transl Oncol 23:931-939). ESAs, however, are recommended for the treatment of symptomatic anemia only at the lowest dose needed to avoid RBC transfusion, given their association with venousthromboembolism, and low or slow Hb response rates. (Escobar et al., supra,' Abdel-Razeq and Hashem (2020) Crit Rev Oncol Hematol 145: 102837; Samaras and Bennett (2008) Am J Hematol Oncol 7:327-332). Furthermore, iron supplementation should be avoided in patients who are receiving concomitant cytotoxic chemotherapy. (Escobar et al., supra).

[0004] Roxadustat, a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, promotes coordinated erythropoiesis through increasing endogenous erythropoietin, improving iron availability, and reducing hepcidin. Administration of roxadustat has been shown to increase red blood cell production while maintaining plasma erythropoietin levels within or near normal physiologic range in multiple subpopulations of chronic kidney disease (CKD) patients, including in the presence of inflammation, and without a need for supplemental intravenous iron. Anemia in CKD patients is substantially due to a reduction in endogenous erythropoietin production by the diseased kidney, that is, CKD produces an erythropoietin-deficiency anemia. Although erythropoietin is almost exclusively made in the kidney, roxadustat surprisingly demonstrated an ability to increase endogenous erythropoietin production even in end-stage renal disease patients.

[0005] Roxadustat is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in CKD patients on dialysis and patients not on dialysis. In an open label, phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non-myeloid malignancies conducted in the United States, roxadustat was reported to be efficacious in patients regardless of tumor type and chemotherapy regimen. (Glaspy et al. (2023) Am J Hematol 98(5):703-711). That study did not compare roxadustat to erythropoiesis-stimulating agents (ESAs), however, and did not seek to identify patients that would benefit from roxadustat over ESAs. The study was also limited in the demographic profile of subjects involved, thereby limiting conclusions that might be drawn with respect to unrepresented or underrepresented classes.

[0006] Therefore, improved treatment options for the management of anemia in patients receiving myelosuppressive chemotherapy are needed.SUMMARY

[0007] Disclosed herein is use of roxadustat in the manufacture of a medicament for treating chemotherapy- induced anemia in a subject receiving multi-cycle platinum or nonplatinum myelosuppressive chemotherapy for a non-myeloid malignancy, wherein the subject has a hemoglobin level <100 g / L prior to treatment and the subject’s blood hemoglobin leveldecreased at least 10 g / L after the initiation of chemotherapy. In some embodiments, the subject has a transferrin saturation (TSAT) >20% and ferritin >100 ng / mL prior to roxadustat treatment. In some embodiments, the subject has C-reactive protein (CRP) level < ULN (upper limit of normal) prior to roxadustat treatment. In some embodiments, the subject has a TSAT >20%, ferritin >100 ng / mL, and a CRP < ULN prior to roxadustat treatment. In some embodiments, the subject has a serum erythropoietin (Epo) level >200 U / L prior to roxadustat treatment. In some embodiments, the subject has an estimated glomerular filtration rate (eGFR) >60 mL / min / 1.73m2prior to roxadustat treatment. In some embodiments, the subject has an Epo level >200 U / L and eGFR >60 mL / min / 1.73m2prior to roxadustat treatment. In some embodiments, the subject has an Epo level >200 U / L, eGFR >60 mL / min / 1.73m2, TSAT >20%, ferritin >100 ng / mL, and a CRP < ULN prior to roxadustat treatment.

[0008] In some embodiments, the subject is receiving multi-cycle platinum myelosuppressive chemotherapy. In some embodiments, the subject is receiving multi-cycle non-platinum myelosuppressive chemotherapy. In some embodiments, the non-myeloid malignancy is selected from the group consisting of breast cancer, lung cancer, gastrointestinal cancers, gynecological cancers, pancreatic cancer, and head and neck cancers. In some embodiments, the subject is receiving chemotherapy for at least 8 weeks after the beginning of treatment.

[0009] In some embodiments, the subject is >18 years old prior to treatment. In some embodiments, the subject weighs >40 kg prior to treatment. In some embodiments, the subject has Eastern Cooperative Oncology Group performance status (ECOG PS) of 0, 1, or 2 prior to treatment. In some embodiments, the subject has a life expectancy of >6 months at the beginning of treatment. In some embodiments, the subject is more than 18 years old, has a diagnosis of non-myeloid malignancy, weighs more than 40 kg, has an ECOG PS of 0, 1 , or 2; and has an estimated life expectancy >6 months prior to treatment with roxadustat.

[0010] In some embodiments, the medicament is labeled for administration to the subject based on a dose of roxadustat relative to body weight of the subject. In some embodiments, the subject has a body weight of 40 to <50 kg and the dose of roxadustat is 50-150 mg, particularly about 100 mg. In some embodiments, the subject has a body weight of 50 to 60 kg and the dose of roxadustat is 70-200 mg, particularly about 120 mg. In some embodiments, the subject has a body weight of >60 kg and the dose of roxadustat is 100-250 mg, particularly about 150 mg. In some embodiments, the subject has a body weight of >60 to <80 kg and the dose of roxadustat is 100-200 mg, particularly about 150 mg. In someembodiments, the subject has a body weight of >80 kg and the dose of roxadustat is 150-250 mg, particularly about 200 mg. In some embodiments, the dose is about 1 to 4 milligrams of roxadustat per kilogram of the subject’s body weight. In some embodiments, the dose is about 1 to 3.5 milligrams of roxadustat per kilogram of the subject’s body weight. In some embodiments, the dose is about 1.5 to 3.5 milligrams of roxadustat per kilogram of the subject’s body weight. In some embodiments, the dose is about 2.0 to 3.5 milligrams of roxadustat per kilogram of the subject’s body weight. In some embodiments, the dose is about 2.0 to 2.5 milligrams of roxadustat per kilogram of the subject’s body weight, particularly about 2.15±0.33 mg / kg.

[0011] In some embodiments, the medicament is labeled to administer a dose of roxadustat three times a week. In some embodiments, the subject has a body weight of 40 to <50 kg and the roxadustat is administered at 50 to 150 mg, particularly about 100 mg, three times per week. In some embodiments, the subject has a body weight of 50 to 60 kg and the roxadustat is administered at 70-200 mg, particularly about 120 mg, three times per week. In some embodiments, the subject has a body weight of >60 kg and the roxadustat is administered at 100-250 mg, particularly about 150 mg, three times per week. In some embodiments, the subject has a body weight of >60 to <80 and the roxadustat is administered at 100-200 mg, particularly about 150 mg, three times per week. In some embodiments, the subject has a body weight of >80 kg and the roxadustat is administered at 150-250 mg, particularly about 200 mg, three times per week.

[0012] In some embodiments, the roxadustat is crystalline Form A characterized by an X-ray powder diffraction pattern comprising peaks at 8.5, 12.8, 16.2, 21.6, 22.9, and 27.4° 20±0.2° 20. In some embodiments the roxadustat is a solid having a unimodal particle size distribution of D90 of 21 pm to 29 pm; a D50 of 12 pm to 17 pm; and a D10 of 6 pm to 10 pm. In some embodiments, the medicament is formulated for oral administration. In some embodiments, the medicament further comprises a pharmaceutically acceptable excipient. In some embodiments, the medicament is formulated in a capsule. In some embodiments, the capsule comprises 20 mg of roxadustat. In some embodiments, the capsule comprises 50 mg of roxadustat. In some embodiments, the capsule comprises a capsule fill and a capsule shell, wherein the capsule fill comprises 20 mg of roxadustat and pharmaceutically acceptable excipients comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the capsule shell is a gelatin shell comprising titanium dioxide, iron oxide yellow, and gelatin. In some embodiments, thecapsule comprises a capsule fill and a capsule shell, wherein the capsule fill comprises 50 mg of roxadustat and pharmaceutically acceptable excipients comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the capsule shell is a gelatin shell comprising Allura red AC, titanium dioxide, iron oxide yellow, and gelatin.

[0013] In some embodiments, the medicament is intended to increase the blood hemoglobin level in the subject following administration compared with the subject’s hemoglobin level prior to administration of the medicament. In some embodiments, the subject reaches and maintains a hemoglobin level of >100 g / L up to 130 g / L during treatment. In some embodiments, the blood hemoglobin level in the subject is increased >10 g / L following administration of the medicament, compared with the subject’s hemoglobin level prior to administration of the medicament, provided the blood hemoglobin level does not exceed 130 g / L. In some embodiments, the blood hemoglobin level in the subject is increased >15 g / L following administration of the medicament, compared with the subject’s hemoglobin level prior to administration of the medicament, provided the blood hemoglobin level does not exceed 130 g / L. In some embodiments, the blood hemoglobin level in the subject is increased >20 g / L following administration of the medicament compared with the subject’s hemoglobin level prior to administration of the medicament, provided the blood hemoglobin level does not exceed 130 g / L. In some embodiments, the subject has a blood hemoglobin level <100 g / L prior to treatment and the subject achieves a hemoglobin level of >110 g / L up to 130 g / L after treatment.

[0014] In particular embodiments, the medicament is labeled for treating anemia in a subject receiving multi-cycle platinum or non-platinum myelosuppressive chemotherapy for a non-myeloid malignancy, wherein the subject has a blood hemoglobin level <100 g / L prior to treatment, and comprises orally administering to the subject 100 mg to 150 mg of roxadustat three times a week, wherein the subject achieves a hemoglobin level of >110 g / L to 130 g / L during treatment. In some embodiments, the medicament is formulated in a capsule wherein said capsule comprises a capsule fill and a capsule shell; wherein the capsule fill comprises 20 mg of roxadustat, 101.84 mg of lactose monohydrate 310, 9.36 mg of microcrystalline cellulose PH101, 6.48 mg of povidone K30, 5.76 mg of croscarmellose sodium, and 0.56 mg of magnesium stearate; and the capsule shell is a gelatin shell comprising titanium dioxide, iron oxide yellow, and gelatin, wherein the titanium dioxide is 1%, by weight of the capsule shell and the iron oxide yellow is 2% by weight of the capsule shell. In some embodiments,the medicament is formulated in a capsule wherein said capsule comprises a capsule fill and a capsule shell; wherein the capsule fill comprises 50 mg of roxadustat, 254.6 mg of lactose monohydrate (310), 23.4 mg of microcrystalline cellulose PH101, 16.20 mg of povidone K30, 14.40 mg of croscarmellose sodium, and 1.4 mg of magnesium stearate; and the capsule shell is a gelatin shell comprising Allura red AC, titanium dioxide, iron oxide yellow, and gelatin, wherein the Allura red AC is 1% by weight of the capsule shell, the titanium dioxide is 1%, by weight of the capsule shell and the iron oxide yellow is 1% by weight of the capsule shell. In some embodiments, the roxadustat is crystalline Form A characterized by an X-ray powder diffraction pattern comprising peaks at 8.5, 12.8, 16.2, 21.6, 22.9, and 27.4° 20±0.2° 20. In some embodiments, the roxadustat has a unimodal particle size distribution of D90 of 21 pm to 29 pm, a D50 of 12 pm to 17 pm, and a D10 of 6 pm to 10 pm.

[0015] In particular embodiments, the medicament is labeled for treating anemia in a subject receiving multi-cycle platinum or non-platinum myelosuppressive chemotherapy for a non-myeloid malignancy, wherein the subject has a blood hemoglobin level <100 g / L prior to treatment, and comprises orally administering to the subject 50 mg to 400 mg of roxadustat three times a week, wherein the blood hemoglobin level in the subject is increased following administration of the roxadustat, compared with the subject’s hemoglobin level prior to administration of the roxadustat provided the blood hemoglobin level does not exceed 130 g / L; provided the roxadustat is administered at least 2 days apart and no more than 4 days apart; and provided that if the subject is receiving paclitaxel as part of the myelosuppressive chemotherapy, roxadustat dosing is held for 24 hours before or after the subject receives the paclitaxel. In various embodiments, the medicament is labeled to provide an amount of roxadustat to be administered to the subject based on the weight of the subject as disclosed herein.

[0016] In particular embodiments, the medicament is labeled for treating anemia in a subject receiving multi-cycle platinum or non-platinum myelosuppressive chemotherapy for a non-myeloid malignancy, wherein the subject has a blood hemoglobin level <100 g / L prior to treatment, and comprises orally administering to the subject 2.0 to 3.5 milligrams of roxadustat per kilogram of the subject’s body weight three times a week, wherein the blood hemoglobin level in the subject is increased following administration of the roxadustat, compared with the subject’s hemoglobin level prior to administration of the roxadustat, provided the blood hemoglobin level does not exceed 130 g / L; provided the roxadustat is administered at least 2 days apart and no more than 4 days apart; provided the dose does notexceed 400 mg; and provided that if the subject is receiving paclitaxel as part of the myelosuppressive chemotherapy, roxadustat dosing is held for 24 hours before or after the subject receives the paclitaxel.

[0017] In some embodiments the medicament is further labeled to optionally increase or decrease the dose of roxadustat until the subject achieves and maintains a blood hemoglobin level of 100 to 120 g / L, providing the dose does not exceed 400 mg. In some embodiments the increasing or decreasing the dose of roxadustat results in a dose of 50 mg, 70 mg, 100 mg, 120 mg, 150 mg, 200 mg, 250 mg, 300 mg, or 400 mg.BRIEF DESCRIPTION OF THE DRAWINGS

[0018] FIG. 1. Is a graphical representation of the study design described in Example 1.

[0019] FIGs. 2A and 2B show the change in hemoglobin (Hb) level from baseline to the level averaged during weeks 9-13. FIG. 2A shows the mean (SE) of absolute Hb from baseline by scheduled visit in the per protocol set (PPS). FIG. 2B shows the mean (SE) of absolute Hb from baseline by scheduled visit in the full analysis set (FAS).

[0020] FIG. 3 shows a Forest plot of primary efficacy results in subgroups.DETAILED DESCRIPTIONDEFINITIONS

[0021] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are now described. All publications cited herein are incorporated herein by reference in their entirety for the purpose of describing and disclosing the methodologies, reagents, and tools reported in the publications that might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

[0022] The articles “a” and “an” as used herein mean “one or more” or “at least one,” unless otherwise indicated. That is, reference to any element of the present invention by the indefinite article “a” or “an” does not exclude the possibility that more than one of the elements is present.

[0023] The term “about” when used before a numerical designation, e.g., temperature, time, amount, and concentration, including a range, indicates approximations which may vary by ±10%, ±5%, or ±1%.

[0024] “Administration” refers to introducing an agent or medicament into a patient. An oral route of administration is preferred for medicaments of the present invention. The related terms and phrases “administering” and “administration of’, when used in connection with an agent or medicament (and grammatical equivalents) refer both to direct administration, which may be administration to a patient by a medical professional or by self-administration by the patient, and / or to indirect administration, which may be the act of prescribing a medicament. For example, a physician who instructs a patient to self-administer a medicament and / or provides a patient with a prescription for a medicament is administering the medicament to the patient. In any event, administration entails delivery of the medicament to the patient.

[0025] The term “anemia” as used herein refers to a reduction in the number of red blood cells and / or level of hemoglobin in blood relative to normal blood levels. For example, a subject is considered anemic when their hematocrit falls below 36% and / or their blood hemoglobin falls below 100 g / L. Anemia can develop in cancer patients undergoing chemotherapy, e.g., with cyclic cisplatin- or non-cisplatin-containing chemotherapeutics.Anemia can also result from disorders in iron transport, processing, and utilization.

[0026] The phrase “chemotherapy” refers to the use of various cytotoxic agents to treat cancer.

[0027] The terms / phrases “chemotherapy-induced anemia”, or “CIA”, or “anemia related to cancer chemotherapy” are used interchangeably and refer to anemia that develops in association with a chemotherapy regimen in a subject undergoing treatment with a chemotherapeutic agent or subjects that have undergone or who are expected to undergo such treatment. Anemia related to chemotherapy can be identified by an anemia that develops after and because of administration of a chemotherapeutic agent. In some embodiments, CIA is identified as a subject having a hemoglobin level <100 g / L and the subject’s blood hemoglobin level decreased at least 10 g / L after the initiation of chemotherapy.

[0028] The phrase “multi-cycle chemotherapy” is a term well known in the art and refers to multiple cycles of chemotherapy. A subject undergoing chemotherapy receives a chemotherapeutic agent for a period of time and then has a rest period. The treatment andrest period make up one treatment cycle. A series of cycles is called a course. A treatment course has multiple cycles.

[0029] “Myelosuppressive chemotherapy” refers to chemotherapy that slows the growth of blood-forming cells in the bone marrow. Myelosuppressive chemotherapy kills normal cells in the bone marrow, thereby lowering the number of normal red blood cells, white blood cells, and platelets in the blood and bone marrow.

[0030] A “non-myeloid malignancy” refers to all malignancies other than myeloid leukemias. The non-myeloid malignancies include all types of carcinomas, sarcoma, melanoma, lymphomas, lymphatic leukemias, and multiple myeloma.

[0031] The term “pharmaceutically acceptable” indicates that the material does not have properties that would cause one of skill in the art to avoid administration of the material to a patient, taking into consideration the disease or conditions to be treated and the respective route of administration. Further, the material is considered to be safe for administration in humans or animals.

[0032] “P -value” or “probability value” is the probability under the assumption of no effect or no difference (null hypothesis) of obtaining a result equal to or more extreme than what was actually observed.

[0033] The terms “subject,” “individual,” or “patient” are used interchangeably and as used herein are intended to include human and non-human animals. Non-human animals include all vertebrates, e.g., mammals and non-mammals, such as non-human primates, sheep, dogs, cats, cows, horses, chickens, amphibians, and reptiles, although mammals are preferred, such as non-human primates, sheep, dogs, cats, cows, and horses. The medicaments are particularly suitable for treating human patients having a disease or disorder described herein.

[0034] “Strength of roxadustat”, “strength of API” or “strength” refer to the amount of roxadustat (compound of Formula (I)) in a particular medicament. It will also be understood that when referring to an “x mg tablet” or “x mg capsule”, x is the amount of roxadustat in the tablet or capsule. For example, a 20 mg capsule means that there is 20 mg of roxadustat in the capsule formulation.

[0035] The term "tablet" refers to a solid dosage form of a pharmaceutical formulation in which the API is blended with one or more pharmaceutically acceptable excipient(s) and compressed into a single solid final dosage form. Tablets can be produced in a wide varietyof sizes, shapes, and surface markings. Tablets may be uncoated or coated by a variety of techniques that are well known in the art. Typically, a tablet comprises a tablet core and a coating.

[0036] The term "tablet core" refers to the inner part of a tablet containing the API and one or more pharmaceutically acceptable excipient(s) compressed into the desired shape but not including the coating. The amount of API in the tablet core can be expressed as a percent of API by weight based on the total weight of the tablet core, % w / w.

[0037] The term "coating" refers to an outer part of a tablet. For tablets as described herein, the coating is applied to the outer surface of the tablet core and typically adheres thereto. The coating may provide one or more of the following properties: taste masking, protecting the API(s) from photodegradation, ease of administration, release modification of the API(s), dust protection, or unique appearance (colors), among other things. Non-limiting examples of coating materials include polyvinylalcohol-based compounds, hydroxyethylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose sodium, polyethylene glycol 4000 and cellulose acetate phthalate. In one embodiment, the coating is a polyvinylalcohol-based coating. The amount of coating that is applied over the outer surface of tablet core can be expressed as a percent of coating by weight based on the weight of the tablet core (% w / w). In one embodiment, the coating may comprise a photostabilizing agent such as a dye. The amount of dye within a coating can be expressed as a percent of dye weight based on the weight of the coating (% w / w). Alternatively, the amount of dye within a coating can be expressed as the amount of the dye applied per surface area unit of the tablet core (mg / cm2).

[0038] “Therapeutically effective” as used herein refers to increasing a subject’s blood hemoglobin level to >100 g / L over a treatment period of 5-9 weeks, and maintaining hemoglobin levels thereafter within a range of >100 g / L to 130 g / L.

[0039] “Treatment”, “treating”, and “treat” are defined as acting upon a disease, disorder, or condition with an agent to reduce or ameliorate the harmful or any other undesired effects of the disease, disorder, or condition and / or its symptoms. Treatment, as used herein, covers the treatment of a human patient, and includes: (a) reducing the risk of occurrence of the condition in a patient determined to be predisposed to the disease but not yet diagnosed as having the condition, (b) impeding the development of the condition, and / or(c) relieving the condition, i.e., causing regression of the condition and / or relieving one or more symptoms of the condition.

[0040] Roxadustat, a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, is a compound of Formula (I):also known as [(4-hydroxy-l-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid. Roxadustat is disclosed in International Publication W02004 / 108681, U.S. Patent 7323475, and China Patent Publication 102977016.

[0041] Roxadustat promotes coordinated erythropoiesis through increasing endogenous erythropoietin, improving iron availability, and reducing hepcidin. Administration of roxadustat has been shown to increase red blood cell production while maintaining plasma erythropoietin levels within or near normal physiologic range in multiple subpopulations of chronic kidney disease (CKD) patients, including in the presence of inflammation, and without a need for supplemental intravenous iron. Anemia in CKD patients is substantially due to a reduction in endogenous erythropoietin production by the diseased kidney, that is, CKD produces an erythropoietin-deficiency anemia. Although erythropoietin is almost exclusively made in the kidney, roxadustat surprisingly demonstrated an ability to increase endogenous erythropoietin production even in end-stage renal disease patients. Roxadustat is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in CKD patients on dialysis and patients not on dialysis.

[0042] Chemotherapy-induced anemia (CIA) results from reduction in red blood cell (RBC) production by the bone marrow due to myelosuppression by chemotherapeutic agents, thereby reducing hemoglobin (Hb) level. While some chemotherapeutic agents, such as cisplatin and ifosfamide, may also produce nephrotoxicity leading to reduced endogenous erythropoietin production, most CIA patients have active kidneys that make erythropoietin in response to the reduction in RBCs caused by chemotherapeutic agents. These patients often present with already high circulating levels of serum erythropoietin even though they are anemic suggesting that increasing endogenous erythropoietin production alone is ofteninsufficient to treat CIA. Thus, unlike the erythropoietin-deficiency anemia produced by CKD, chemotherapy-induced anemia is primarily due to defective erythroid progenitor proliferation in the bone marrow.

[0043] The present invention provides a use of roxadustat in the manufacture of a medicament for treating CIA. In some embodiments, the invention provides use of roxadustat in manufacture of a medicament for treating anemia in a subject receiving multicycle platinum or non-platinum myelosuppressive chemotherapy for a non-myeloid malignancy, wherein the subject has a hemoglobin level <100 g / L prior to treatment and the subject’s blood hemoglobin level decreased at least 10 g / L after the initiation of chemotherapy. In some embodiments, the subject has a transferrin saturation (TSAT) >20% and ferritin >100 ng / mL prior to treatment. In some embodiments, the subject has C-reactive protein (CRP) level < ULN (upper limit of normal) prior to treatment. In some embodiments, the subject has a TSAT >20%, ferritin >100 ng / mL, and a CRP < ULN prior to treatment. In some embodiments, the subject has a serum erythropoietin (Epo) level >200 U / L prior to treatment. In some embodiments, the subject has an estimated glomerular filtration rate (eGFR) >60 mL / min / 1.73m2prior to treatment. In some embodiments, the subject has an Epo level >200 U / L and eGFR >60 mL / min / 1.73m2prior to treatment. In some embodiments, the subject has an Epo level >200 U / L, eGFR >60 mL / min / 1.73m2, TSAT >20%, ferritin >100 ng / mL, and a CRP < ULN prior to treatment.

[0044] Transferrin is a blood plasma glycoprotein that is for transport of ferric ions through the blood to various tissues, such as the liver, spleen, and bone marrow. Each transferrin molecule contains binding sites for two ferric ions, and the extent to which the full complement of these binding sites on transferrin in the blood are occupied by ferric ions is referred to as transferrin saturation (TSAT). Ferritin, on the other hand, is the primary intracellular iron-storage protein keeping iron in a soluble and non-toxic form. Ferritin is found in most tissues as a cytosolic protein, but small amounts are secreted into the serum where this plasma ferritin serves as an indirect marker of the total amount of iron stored in the body. This iron regulatory system is often disrupted during inflammation, leading to increased sequestration of iron in storage and reduced circulating iron. High serum ferritin with low TSAT levels may imply a condition of iron sequestration.

[0045] C-reactive protein (CRP) is an acute-phase reactant protein found in blood plasma, whose circulating concentrations rise during the acute phase of an inflammatory / infectious process. Thus, elevated CRP levels are also an indication ofpotential inflammation and resulting iron sequestration. In subjects having TSAT >20%, ferritin >100 ng / mL, and a CRP < ULN, iron sequestration and a resulting anemia due to inflammation are unlikely. Thus, anemia in these subjects is likely due to another cause.

[0046] Erythropoietin (Epo) is a glycoprotein cytokine secreted mainly by the kidneys in response to cellular hypoxia that stimulates red blood cell production in the bone marrow. Low levels of Epo (around 10 mU / mL) are constantly secreted in sufficient quantities to compensate for normal red blood cell turnover, but elevated levels of Epo (up to 10,000 mU / mL) occur due to kidney hypoxia generally resulting from anemia or lung dysfunction. In patients with chronic kidney disease (CKD), normochromic normocytic anemia may develop due to Epo deficiency. As the glomerular filtration rate (GFR) falls below 60 mL / min / 1.73 m2 (Stage 3a CKD), Epo production by the kidneys falls and anemia due to CKD results. Both erythropoiesis-stimulating agents (ESAs, e.g., SEPO® recombinant human erythropoietin injection (hereinafter “SEPO”), Shenyang Sunshine Pharmaceuticals CO., Ltd, Shenyang, China) and roxadustat have been approved for use in treating anemia due to CKD. In subjects having Epo level >200 U / L and eGFR >60 mL / min / 1.73m2, CKD and an anemia resulting therefrom are unlikely. Thus, anemia in these subjects is likely due to another cause.

[0047] In a direct comparison between an ESA and roxadustat in subjects receiving multi-cycle platinum or non-platinum myelosuppressive chemotherapy for a non-myeloid malignancy, roxadustat generally performed better than ESA in subgroups having TSAT >20% and ferritin >100 ng / mL, CRP < ULN, and / or Epo level >200 U / L. These subjects may be the most representative of subjects having anemia principally if not exclusively resulting from administration of a myelosuppressive chemotherapeutic agent. Thus, roxadustat is surprisingly beneficial in the treatment of CIA.

[0048] The present invention therefore provides use of roxadustat for manufacture of a medicament for treating CIA in subjects receiving multi-cycle platinum or non-platinum myelosuppressive chemotherapy for a non-myeloid malignancy. The effectiveness of roxadustat is independent of the type of non-myeloid malignancy in the subject or chemotherapeutic agent being used. Furthermore, compared to treatment with an ESA, numerically higher proportions of subjects treated with roxadustat achieved >10, 15, and 20 g / L Hb increase, and shorter times were needed to achieve >15 and 20 g / L Hb increases in the roxadustat group than in the ESA group (42.0 days vs 52.0 days for >15 g / L Hb increase and 57.0 days vs 77.0 days for >20 g / L Hb increase, respectively). The difference of 20 daysbetween roxadustat and ESA in the time to reach a >20 g / L increase may be clinically significant in patients who are receiving regular chemotherapy, e.g., 3-week regimen, because the patients may achieve the desired Hb level approximately one cycle earlier when treated with roxadustat instead of ESA.

[0049] In one aspect the invention provides a use of roxadustat in manufacture of a medicament for treating anemia in a subject receiving multi-cycle platinum or non-platinum myelosuppressive chemotherapy for a non-myeloid malignancy, wherein the medicament is administered to the subject at a dose of 50 to 400 milligrams of roxadustat wherein the anemia is treated. More specifically, the invention provides a use of roxadustat in manufacture of a medicament for treating anemia in a subject receiving multi-cycle platinum or non-platinum myelosuppressive chemotherapy for a non-myeloid malignancy, wherein the medicament is administered to the subject at a dose of 100 to 150 milligrams of roxadustat 2 to 3 times per week, wherein the anemia is treated.

[0050] In one aspect, the invention provides a use of roxadustat in manufacture of a medicament for treating anemia in a subject receiving multi-cycle platinum or non-platinum myelosuppressive chemotherapy for a non-myeloid malignancy, wherein the medicament is administered to the subject at a dose of about 1 to 4 milligrams of roxadustat per kilogram of the subject’s body weight wherein the anemia is treated. More specifically, the invention provides a use of roxadustat in manufacture of a medicament for treating anemia in a subject receiving multi-cycle platinum or non-platinum myelosuppressive chemotherapy for a non- myeloid malignancy, wherein the medicament is administered to the subject at a dose of about 2.0 to 3.5 milligrams of roxadustat per kilogram of the subject’s body weight 2 to 3 times per week wherein the anemia is treated.

[0051] The present invention also provides a method for treating CIA in a subject in need thereof, comprising administering to the subject, roxadustat whereby the anemia is treated. In some embodiments, the invention provides a method of treating anemia in a subject receiving multi-cycle platinum or non-platinum myelosuppressive chemotherapy for a non-myeloid malignancy, wherein the subject has a hemoglobin level <100 g / L prior to treatment and the subject’s blood hemoglobin level decreased at least 10 g / L after the initiation of chemotherapy. In some embodiments, the subject has a transferrin saturation (TSAT) >20% and ferritin >100 ng / mL prior to treatment. In some embodiments, the subject has C-reactive protein (CRP) level < ULN (upper limit of normal) prior to treatment. In some embodiments, the subject has a TSAT >20%, ferritin >100 ng / mL, and a CRP < ULNprior to treatment. In some embodiments, the subject has a serum erythropoietin (Epo) level >200 U / L prior to treatment. In some embodiments, the subject has an estimated glomerular filtration rate (eGFR) >60 mL / min / 1.73m2prior to treatment. In some embodiments, the subject has an Epo level >200 U / L and eGFR >60 mL / min / 1.73m2prior to treatment. In some embodiments, the subject has an Epo level >200 U / L, eGFR >60 mL / min / 1.73m2, TSAT >20%, ferritin >100 ng / mL, and a CRP < ULN prior to treatment.

[0052] The present invention also provides a method for treating CIA in a subject receiving multi-cycle platinum or non-platinum myelosuppressive chemotherapy for a non- myeloid malignancy, comprising administering to the subject, a dose of 50 to 400 milligrams of roxadustat wherein the anemia is treated. More specifically, the invention provides a method for treating CIA in a subject receiving multi-cycle platinum or non-platinum myelosuppressive chemotherapy for a non-myeloid malignancy, comprising administering to the subject, a dose of 100 to 150 milligrams of roxadustat 2 to 3 times per week, wherein the anemia is treated.

[0053] In one aspect, the invention provides method for treating CIA in a subject receiving multi-cycle platinum or non-platinum myelosuppressive chemotherapy for a non- myeloid malignancy, comprising administering to the subject, a dose of about 1 to 4 milligrams of roxadustat per kilogram of the subject’s body weight wherein the anemia is treated. More specifically, the invention provides a method for treating CIA in a subject receiving multi-cycle platinum or non-platinum myelosuppressive chemotherapy for a non- myeloid malignancy, comprising administering to the subject, a dose of about 2.0 to 3.5 milligrams of roxadustat per kilogram of the subject’s body weight 2 to 3 times per week wherein the anemia is treated.

[0054] Roxadustat

[0055] In some embodiments, the roxadustat according to any embodiment described herein is amorphous, an anhydrous polymorph, a solvate, a hydrate or a hemihydrate. In some embodiments the roxadustat according to any embodiment described herein, is as described in International Patent Publication WO2014 / 014835, U.S. Patent 8883823, and China Patent Publication 107382859; each of which is herein incorporated by reference in its entirety. In some embodiments, the roxadustat according to any embodiment described herein is amorphous, crystalline form A, crystalline form B, crystalline form C or crystalline form D, as described in WO2014 / 014835. In some embodiments, the roxadustat according to anyembodiment described herein is an amorphous solid. In some embodiments, the roxadustat according to any embodiment described herein is crystalline form A or crystalline form B. In some embodiments, the roxadustat according to any embodiment described herein is crystalline form A characterized by an X-ray powder diffraction pattern comprising peaks at 8.5, 16.2, and 27.4° 29±0.2° 29. In some embodiments, the roxadustat according to any embodiment described herein is crystalline form A characterized by an X-ray powder diffraction pattern comprising peaks at 8.5, 12.8, 16.2, 21.6, 22.9, and 27.4° 29±9.2° 29. In some embodiments, the roxadustat according to any embodiment described herein is crystalline form A, characterized by an X-ray powder diffraction pattern as shown in Table 1.

[0056] Table 1: X-Ray Powder Diffraction Pattern of Crystal Form A ofRoxadustat

[0057] In some embodiments, the roxadustat according to any embodiment described herein has a particle size distribution as described in China Patent Publication 116199628 and / or PCT / US2024 / 026159, each of which is herein incorporated by reference in its entirety. In some embodiments, the roxadustat is a solid having a unimodal particle distribution of D90 of 21 pm to 29 pm; a D50 of 12 pm to 17 pm; and a DIO of 6 pm to 10 pm. In some embodiments, the roxadustat is crystalline form A having a unimodal particle distribution of D90 of 21 pm to 29 pm; a D50 of 12 pm to 17 pm; and a DIO of 6 pm to 10 pm.

[0058] Medicaments of roxadustat

[0059] In one aspect, the medicament comprises roxadustat alone. In another aspect, the medicament comprises roxadustat and at least one pharmaceutically acceptable excipient. In some embodiments, the medicament comprises roxadustat and at least one pharmaceutically acceptable excipient formulated for oral administration. In some embodiments, the medicament formulated for oral administration is as described in International Patent Application Publication WO2014 / 197660, U.S. Patent 10765672, China Patent Application Publication 111728951, China Patent Publication 116199628 and / or PCT / US2024 / 026159, each of which is herein incorporated by reference in its entirety.

[0060] In some embodiments, the medicament according to any embodiment described herein is an oral pharmaceutical composition, wherein the excipient of the roxadustat oral pharmaceutical composition is selected from the group consisting of a diluent, a binder, a disintegrant, and a lubricant, or combinations thereof. In some embodiments, the roxadustat oral pharmaceutical composition according to any embodiment described herein further comprises a photostabilizer. In some embodiments, the photostabilizer is selected from one or more of Allura Red AC, Allura Red AC Aluminum Lake, titanium dioxide, and iron oxide yellow. In some embodiments, the photostabilizer comprises titanium dioxide and iron oxide yellow. In some embodiments, the photostabilizer comprises Allura Red AC, titaniumdioxide, and iron oxide yellow. In some embodiments the photostabilizer comprises titanium dioxide and Allura Red AC or Allura Red AC aluminum lake.

[0061] In some embodiments, the medicament according to any embodiment described herein is a tablet or a capsule. In some embodiments the medicament according to any embodiment described herein is a capsule. In some embodiments, the medicament according to any embodiment described herein is a capsule comprising 20 mg of roxadustat and at least one appropriate excipient for oral capsule delivery. In some embodiments the medicament according to any embodiment described herein is a capsule comprising 50 mg of roxadustat and at least one appropriate excipient for oral capsule delivery.

[0062] In some embodiments, the medicament according to any embodiment described herein is a capsule comprising a capsule fill and a capsule shell wherein: the capsule fill comprises 20 mg of roxadustat according to any embodiment described herein and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the capsule shell is a gelatin shell comprising titanium dioxide, iron oxide yellow, and gelatin. In some embodiments, the capsule fill comprises lactose monohydrate (310), microcrystalline cellulose PHI 01, povidone K30, croscarmellose sodium, and magnesium stearate. In some embodiments, the capsule fill comprises 101.84 mg of lactose monohydrate (310), 9.36 mg of microcrystalline cellulose PH101, 6.48 mg of povidone K30, 5.76 mg of croscarmellose sodium, and 0.56 mg of magnesium stearate. In some embodiments, the titanium dioxide and iron oxide yellow comprise 3% by weight of the capsule shell. In some embodiments, the titanium dioxide is 1% by weight of the capsule shell, and the iron oxide yellow is 2% by weight of the capsule shell.

[0063] In some embodiments, the medicament according to any embodiment described herein is a capsule comprising a capsule fill and a capsule shell wherein: the capsule fill comprises 20 mg of solid roxadustat wherein the solid roxadustat has a unimodal particle distribution of D90 of about 21 pm to 29 pm; a D50 of about 12 pm to 17 pm; and a D10 of about 6 pm to 10 pm; and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the capsule shell is a gelatin shell comprising titanium dioxide, iron oxide yellow, and gelatin. In some embodiments, the capsule fill comprises lactose monohydrate (310), microcrystalline cellulose PH101, povidone K30, croscarmellose sodium, and magnesium stearate. In some embodiments, the capsule fill comprises 101.84 mg of lactosemonohydrate (310), 9.36 mg of microcrystalline cellulose PH101, 6.48 mg of povidone K30, 5.76 mg of croscarmellose sodium, and 0.56 mg of magnesium stearate. In some embodiments, the titanium dioxide and iron oxide yellow comprise 3% by weight of the capsule shell. In some embodiments, the titanium dioxide is 1%, by weight of the capsule shell and the iron oxide yellow is 2% by weight of the capsule shell.

[0064] In some embodiments, the medicament according to any embodiment described herein is a capsule comprising a capsule fill and a capsule shell wherein: the capsule fill comprises 20 mg of solid roxadustat, wherein the roxadustat is roxadustat Form A characterized by an X-ray powder diffraction pattern comprising peaks at 8.5, 12.8, 16.2, 21.6, 22.9, and 27.4° 20±O.2° 20; and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the capsule shell is a gelatin shell comprising titanium dioxide, iron oxide yellow, and gelatin. In some embodiments, the capsule fill comprises lactose monohydrate (310), microcrystalline cellulose PH 101, povidone K30, croscarmellose sodium, and magnesium stearate. In some embodiments, the capsule fill comprises 101.84 mg of lactose monohydrate (310), 9.36 mg of microcrystalline cellulose PH101, 6.48 mg of povidone K30, 5.76 mg of croscarmellose sodium, and 0.56 mg of magnesium stearate. In some embodiments, the titanium dioxide and iron oxide yellow comprise 3% by weight of the capsule shell. In some embodiments, the titanium dioxide is 1% by weight of the capsule shell and the iron oxide yellow is 2% by weight of the capsule shell.

[0065] In some embodiments, the medicament according to any embodiment described herein is a capsule comprising a capsule fill and a capsule shell wherein: the capsule fill comprises 20 mg of solid roxadustat, wherein the roxadustat is roxadustat Form A characterized by an X-ray powder diffraction pattern comprising peaks at 8.5, 12.8, 16.2, 21.6, 22.9, and 27.4° 20±O.2° 20; and having a unimodal particle distribution of D90 of about 21 pm to 29 pm, a D50 of about 12 pm to 17 pm, and a D10 of about 6 pm to 10 pm; and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the capsule shell is a gelatin shell comprising titanium dioxide, iron oxide yellow, and gelatin. In some embodiments, the capsule fill comprises lactose monohydrate (310), microcrystalline cellulose PHI 01, povidone K30, croscarmellose sodium, and magnesium stearate. In some embodiments, the capsule fill comprises 101.84 mg of lactose monohydrate (310), 9.36 mg of microcrystalline cellulose PH101, 6.48 mg of povidone K30, 5.76 mg of croscarmellosesodium, and 0.56 mg of magnesium stearate. In some embodiments, the titanium dioxide and iron oxide yellow comprise 3% by weight of the capsule shell. In some embodiments, the titanium dioxide is 1% by weight of the capsule shell and the iron oxide yellow is 2% by weight of the capsule shell.

[0066] In some embodiments, the medicament according to any embodiment described herein is a capsule comprising a capsule fill and a capsule shell wherein: the capsule fill comprises 20 mg of solid roxadustat, wherein the roxadustat is roxadustat Form A characterized by an X-ray powder diffraction pattern comprising peaks at 8.5, 12.8, 16.2, 21.6, 22.9, and 27.4° 20±O.2° 20; and having a unimodal particle distribution of D90 of about 21 pm to 29 pm, a D50 of about 12 pm to 17 pm, and a D10 of about 6 pm to 10 pm; and a pharmaceutically acceptable excipient comprising 101.84 mg of lactose monohydrate (310), 9.36 mg of microcrystalline cellulose PH101, 6.48 mg of povidone K30, 5.76 mg of croscarmellose sodium, and 0.56 mg of magnesium stearate; and the capsule shell is a gelatin shell comprising titanium dioxide, iron oxide yellow, and gelatin; wherein the titanium dioxide is 1% by weight of the capsule shell and the iron oxide yellow is 2% by weight of the capsule shell.

[0067] In some embodiments, the medicament according to any embodiment described herein is a capsule comprising a capsule fill and a capsule shell wherein: the capsule fill comprises 50 mg of roxadustat and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the capsule shell is a gelatin shell comprising Allura red AC, titanium dioxide, iron oxide yellow, and gelatin. In some embodiments, the capsule fill comprises lactose monohydrate (310), microcrystalline cellulose PH101, povidone K30, croscarmellose sodium, and magnesium stearate. In some embodiments, the capsule fill comprises 254.6 mg of lactose monohydrate (310), 23.4 mg of microcrystalline cellulose PH101, 16.20 mg of povidone K30, 14.40 mg of croscarmellose sodium, and 1.4 mg of magnesium stearate. In some embodiments, the Allura red AC, titanium dioxide, and iron oxide yellow comprise 3% by weight of the capsule shell. In some embodiments the Allura red AC is 1% by weight of the capsule shell, the titanium dioxide is 1%, by weight of the capsule shell, and the iron oxide yellow is 1% by weight of the capsule shell.

[0068] In some embodiments, the medicament according to any embodiment described herein is a capsule comprising a capsule fill and a capsule shell wherein: the capsule fill comprises 50 mg of solid roxadustat, wherein the roxadustat has a unimodal particledistribution of D90 of about 21 pm to 29 pm, a D50 of about 12 pm to 17 pm, and a DIO of about 6 pm to 10 pm; and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the capsule shell is a gelatin shell comprising Allura red AC, titanium dioxide, iron oxide yellow, and gelatin. In some embodiments, the capsule fill comprises lactose monohydrate (310), microcrystalline cellulose PH 101, povidone K30, croscarmellose sodium, and magnesium stearate. In some embodiments, the capsule fill comprises 254.6 mg of lactose monohydrate (310), 23.4 mg of microcrystalline cellulose PH101, 16.20 mg of povidone K30, 14.40 mg of croscarmellose sodium, and 1.4 mg of magnesium stearate. In some embodiments, the Allura red AC, titanium dioxide, and iron oxide yellow comprise 3% by weight of the capsule shell. In some embodiments, the Allura red AC is 1% by weight of the capsule shell, the titanium dioxide is 1%, by weight of the capsule shell, and the iron oxide yellow is 1% by weight of the capsule shell.

[0069] In some embodiments, the medicament according to any embodiment described herein is a capsule comprising a capsule fill and a capsule shell wherein: the capsule fill comprises 50 mg of solid roxadustat, wherein the roxadustat is roxadustat Form A characterized by an X-ray powder diffraction pattern comprising peaks at 8.5, 12.8, 16.2, 21.6, 22.9, and 27.4° 20±O.2° 20; and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate,; and the capsule shell is a gelatin shell comprising Allura red AC, titanium dioxide, iron oxide yellow, and gelatin. In some embodiments, the capsule fill comprises lactose monohydrate (310), microcrystalline cellulose PH101, povidone K30, croscarmellose sodium, and magnesium stearate. In some embodiments, the capsule fill comprises 254.6 mg of lactose monohydrate (310), 23.4 mg of microcrystalline cellulose PH101, 16.20 mg of povidone K30, 14.40 mg of croscarmellose sodium, and 1.4 mg of magnesium stearate. In some embodiments, the Allura red AC, titanium dioxide, and iron oxide yellow comprise 3% by weight of the capsule shell. In some embodiments the Allura red AC is 1% by weight of the capsule shell, the titanium dioxide is 1%, by weight of the capsule shell, and the iron oxide yellow is 1% by weight of the capsule shell.

[0070] In some embodiments, the medicament according to any embodiment described herein is a capsule comprising a capsule fill and a capsule shell wherein: the capsule fill comprises 50 mg of solid roxadustat, wherein the roxadustat is roxadustat Form A characterized by an X-ray powder diffraction pattern comprising peaks at 8.5, 12.8, 16.2,21.6, 22.9, and 27.4° 29±0.2° 29; and having a unimodal particle distribution of D99 of about 21 pm to 29 pm, a D59 of about 12 pm to 17 pm, and a D19 of about 6 pm to 19 pm; and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the capsule shell is a gelatin shell comprising Allura red AC, titanium dioxide, iron oxide yellow, and gelatin. In some embodiments, the capsule fill comprises lactose monohydrate (319), microcrystalline cellulose PHI 91, povidone K39, croscarmellose sodium, and magnesium stearate. In some embodiments, the capsule fill comprises 254.6 mg of lactose monohydrate (319), 23.4 mg of microcrystalline cellulose PHI 91, 16.29 mg of povidone K39, 14.49 mg of croscarmellose sodium, and 1.4 mg of magnesium stearate. In some embodiments, the Allura red AC, titanium dioxide, and iron oxide yellow comprise 3% by weight of the capsule shell. In some embodiments, the Allura red AC is 1% by weight of the capsule shell, the titanium dioxide is 1%, by weight of the capsule shell, and the iron oxide yellow is 1% by weight of the capsule shell.

[0071] In some embodiments, the medicament according to any embodiment described herein is a capsule comprising a capsule fill and a capsule shell wherein: the capsule fill comprises 50 mg of solid roxadustat, wherein the roxadustat is roxadustat Form A characterized by an X-ray powder diffraction pattern comprising peaks at 8.5, 12.8, 16.2, 21.6, 22.9, and 27.4° 29±0.2° 29; and having a unimodal particle distribution of D90 of about 21 pm to 29 pm, a D50 of about 12 pm to 17 pm, and a DIO of about 6 pm to 10 pm; and a pharmaceutically acceptable excipient comprising 254.6 mg of lactose monohydrate (310), 23.4 mg of microcrystalline cellulose PH101, 16.20 mg of povidone K30, 14.40 mg of croscarmellose sodium, and 1.4 mg of magnesium stearate; and the capsule shell is a gelatin shell comprising Allura red AC, titanium dioxide, iron oxide yellow, and gelatin; wherein the Allura red AC is 1% by weight of the capsule shell, the titanium dioxide is 1%, by weight of the capsule shell, and the iron oxide yellow is 1% by weight of the capsule shell.

[0072] It will be understood by one of skill in the art that more than one roxadustat medicament may be administered to a subject to achieve a desired dose. For example, if the subject requires a dose of 100 mg of roxadustat, this dose can be achieved by administration of two 50 mg capsules or tablets taken concurrently or a dose of 100 mg can be achieved by administration of five 20 mg tablets or capsules. A 120 mg dose of roxadustat can be achieved, for example, by administration of a 70 mg tablet or capsule and a 50 mg tablet or capsule; by administration of six 20 mg tablets or capsules; or by administration or two 50mg tablets or capsules and one 20 mg tablet or capsule. A 150 mg dose can be achieved, for example, by administration of one 150 mg tablet or capsule; by administration of three 50 mg tablets or capsules; by administration of a 100 mg tablet or capsule and a 50 mg tablet or capsule; or by administration of a 50 mg tablet or capsule and five 20 mg tablets or capsules.

[0073] In some embodiments the medicament according to any embodiment described herein is a tablet. In some embodiments, the medicament according to any embodiment described herein is a tablet comprising 20 mg of roxadustat and at least one appropriate excipient for oral tablet delivery. In some embodiments the medicament according to any embodiment described herein is a tablet comprising 50 mg of roxadustat and at least one appropriate excipient for oral tablet delivery. In some embodiments the medicament according to any embodiment described herein is a tablet comprising 70 mg of roxadustat and at least one appropriate excipient for oral tablet delivery. In some embodiments the medicament according to any embodiment described herein is a tablet comprising 100 mg of roxadustat and at least one appropriate excipient for oral tablet delivery. In some embodiments the medicament according to any embodiment described herein is a tablet comprising 150 mg of roxadustat and at least one appropriate excipient for oral tablet delivery.

[0074] In some embodiments, the medicament according to any embodiment described herein is a tablet comprising a tablet core and a coating wherein: the tablet core comprises 20 mg of roxadustat according to any embodiment described herein and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises Allura Red AC in aluminum lake and titanium dioxide. In some embodiments, the tablet core comprises lactose monohydrate, microcrystalline cellulose, povidone K30, croscarmellose sodium, and magnesium stearate. In some embodiments, the tablet core comprises 42.6 mg of lactose monohydrate, 9.12 mg of microcrystalline cellulose, 3.6 mg of povidone K30, 4.0 mg of croscarmellose sodium and 0.68 mg of magnesium stearate. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin. In some embodiments the coating comprises 0.1 to 0.4 mg / cm2titanium dioxide, and 0.1 -0.4 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. In some embodiments the coating comprises 0.293 mg / cm2titanium dioxide, and 0.286 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. In some embodiments the surface area of the tablet is 0.894 cm2. In someembodiments the coating comprises 0.293 mg / cm2titanium dioxide, and 0.286 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet and the surface area of the tablet is 0.894 cm2. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, 0.293 mg / cm2titanium dioxide based on surface area of the tablet, 0.286 mg / cm2Allura Red AC in aluminum lake based on surface are of the tablet, and lecithin; and the surface area of the tablet is 0.894 cm2. In some embodiments the coating comprises 2.64 mg poly vinyl alcohol, 1.20 mg talc, 0.74 mg macrogol 3350, 0.28 mgtitanium dioxide, 0.58 mg Allura Red AC in aluminum lake 38-42%, 0.34 mg Allura Red AC in aluminum lake 15- 17% and 0.21 mg lecithin. In some embodiments the tablet core comprises 42.6 mg of lactose monohydrate, 9.12 mg of microcrystalline cellulose, 3.6 mg of povidone K30, 4.0 mg of croscarmellose sodium and 0.68 mg of magnesium stearate and the coating comprises 2.64 mg poly vinyl alcohol, 1.20 mg talc, 0.74 mg macrogol 3350, 0.28 mgtitanium dioxide, 0.58 mg Allura Red AC in aluminum lake 38-42%, 0.34 mg Allura Red AC in aluminum lake 15- 17% and 0.21 mg lecithin.

[0075] In some embodiments, the medicament according to any embodiment described herein is a tablet comprising a tablet core and a coating wherein: the tablet comprises 20 mg of solid roxadustat wherein the solid roxadustat has a unimodal particle distribution of D90 of about 21 pm to 29 pm; a D50 of about 12 pm to 17 pm; and a D10 of about 6 pm to 10 pm; and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises Allura Red AC in aluminum lake and titanium dioxide. In some embodiments, the tablet core comprises lactose monohydrate, microcrystalline cellulose, povidone K30, croscarmellose sodium, and magnesium stearate. In some embodiments, the tablet core comprises 42.6 mg of lactose monohydrate, 9.12 mg of microcrystalline cellulose, 3.6 mg of povidone K30, 4.0 mg of croscarmellose sodium and 0.68 mg of magnesium stearate. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin. In some embodiments the coating comprises 0.1 to 0.4 mg / cm2titanium dioxide, and 0.1-0.4 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. In some embodiments the coating comprises 0.293 mg / cm2titanium dioxide, and 0.286 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. In some embodiments the surface area of the tablet is 0.894 cm2. In some embodiments the coating comprises 0.293 mg / cm2titanium dioxide, and 0.286 mg / cm2Allura Red AC in aluminum lake, based on the surface area of thetablet and the surface area of the tablet is 0.894 cm2. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, 0.293 mg / cm2titanium dioxide based on surface area of the tablet, 0.286 mg / cm2Allura Red AC in aluminum lake based on surface are of the tablet, and lecithin; and the surface area of the tablet is 0.894 cm2. In some embodiments the coating comprises 2.64 mg poly vinyl alcohol, 1.20 mg talc, 0.74 mg macrogol 3350, 0.28 mg titanium dioxide, 0.58 mg Allura Red AC in aluminum lake 38-42%, 0.34 mg Allura Red AC in aluminum lake 15-17% and 0.21 mg lecithin. In some embodiments the tablet core comprises 42.6 mg of lactose monohydrate, 9.12 mg of microcrystalline cellulose, 3.6 mg of povidone K30, 4.0 mg of croscarmellose sodium and 0.68 mg of magnesium stearate and the coating comprises 2.64 mg poly vinyl alcohol, 1.20 mg talc, 0.74 mg macrogol 3350, 0.28 mgtitanium dioxide, 0.58 mg Allura Red AC in aluminum lake 38-42%, 0.34 mg Allura Red AC in aluminum lake 15-17% and 0.21 mg lecithin.

[0076] In some embodiments, the medicament according to any embodiment described herein is a tablet comprising a tablet core and a coating wherein: the tablet core comprises 20 mg of solid roxadustat, wherein the roxadustat is roxadustat Form A characterized by an X- ray powder diffraction pattern comprising peaks at 8.5, 12.8, 16.2, 21.6, 22.9, and 27.4° 20±0.2° 20; and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises Allura Red AC in aluminum lake and titanium dioxide. In some embodiments, the tablet core comprises lactose monohydrate, microcrystalline cellulose, povidone K30, croscarmellose sodium, and magnesium stearate. In some embodiments, the tablet core comprises 42.6 mg of lactose monohydrate, 9.12 mg of microcrystalline cellulose, 3.6 mg of povidone K30, 4.0 mg of croscarmellose sodium and 0.68 mg of magnesium stearate. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin. In some embodiments the coating comprises 0.1 to 0.4 mg / cm2titanium dioxide, and 0.1-0.4 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. In some embodiments the coating comprises 0.293 mg / cm2titanium dioxide, and 0.286 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. In some embodiments the surface area of the tablet is 0.894 cm2. In some embodiments the coating comprises 0.293 mg / cm2titanium dioxide, and 0.286 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet and the surface area of the tablet is 0.894 cm2. In some embodiments the coatingcomprises poly vinyl alcohol, talc, macrogol 3350, 0.293 mg / cm2titanium dioxide based on surface area of the tablet, 0.286 mg / cm2Allura Red AC in aluminum lake based on surface are of the tablet, and lecithin; and the surface area of the tablet is 0.894 cm2. In some embodiments the coating comprises 2.64 mg poly vinyl alcohol, 1.20 mg talc, 0.74 mg macrogol 3350, 0.28 mg titanium dioxide, 0.58 mg Allura Red AC in aluminum lake 38-42%, 0.34 mg Allura Red AC in aluminum lake 15-17% and 0.21 mg lecithin. In some embodiments the tablet core comprises 42.6 mg of lactose monohydrate, 9.12 mg of microcrystalline cellulose, 3.6 mg of povidone K30, 4.0 mg of croscarmellose sodium and 0.68 mg of magnesium stearate and the coating comprises 2.64 mg poly vinyl alcohol, 1.20 mg talc, 0.74 mg macrogol 3350, 0.28 mgtitanium dioxide, 0.58 mg Allura Red AC in aluminum lake 38-42%, 0.34 mg Allura Red AC in aluminum lake 15-17% and 0.21 mg lecithin.

[0077] In some embodiments, the medicament according to any embodiment described herein is a tablet comprising a tablet core and a coating wherein: the tablet core comprises 20 mg of solid roxadustat, wherein the roxadustat is roxadustat Form A characterized by an X- ray powder diffraction pattern comprising peaks at 8.5, 12.8, 16.2, 21.6, 22.9, and 27.4° 20±0.2° 20; and having a unimodal particle distribution of D90 of about 21 pm to 29 pm, a D50 of about 12 pm to 17 pm, and a D10 of about 6 pm to 10 pm; and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises Allura Red AC in aluminum lake and titanium dioxide. In some embodiments, the tablet core comprises lactose monohydrate, microcrystalline cellulose, povidone K30, croscarmellose sodium, and magnesium stearate. In some embodiments, the tablet core comprises 42.6 mg of lactose monohydrate, 9.12 mg of microcrystalline cellulose, 3.6 mg of povidone K30, 4.0 mg of croscarmellose sodium and 0.68 mg of magnesium stearate. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin. In some embodiments the coating comprises 0.1 to 0.4 mg / cm2titanium dioxide, and 0.1 -0.4 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. In some embodiments the coating comprises 0.293 mg / cm2titanium dioxide, and 0.286 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. In some embodiments the surface area of the tablet is 0.894 cm2. In some embodiments the coating comprises 0.293 mg / cm2titanium dioxide, and 0.286 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet and the surface area of thetablet is 0.894 cm2. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, 0.293 mg / cm2titanium dioxide based on surface area of the tablet, 0.286 mg / cm2Allura Red AC in aluminum lake based on surface are of the tablet, and lecithin; and the surface area of the tablet is 0.894 cm2. In some embodiments the coating comprises 2.64 mg poly vinyl alcohol, 1.20 mg talc, 0.74 mg macrogol 3350, 0.28 mgtitanium dioxide, 0.58 mg Allura Red AC in aluminum lake 38-42%, 0.34 mg Allura Red AC in aluminum lake 15- 17% and 0.21 mg lecithin. In some embodiments the tablet core comprises 42.6 mg of lactose monohydrate, 9.12 mg of microcrystalline cellulose, 3.6 mg of povidone K30, 4.0 mg of croscarmellose sodium and 0.68 mg of magnesium stearate and the coating comprises 2.64 mg poly vinyl alcohol, 1.20 mg talc, 0.74 mg macrogol 3350, 0.28 mgtitanium dioxide, 0.58 mg Allura Red AC in aluminum lake 38-42%, 0.34 mg Allura Red AC in aluminum lake 15- 17% and 0.21 mg lecithin.

[0078] In some embodiments, the medicament according to any embodiment described herein is a tablet comprising a tablet core and a coating wherein: the tablet core comprises 20 mg of solid roxadustat, wherein the roxadustat is roxadustat Form A characterized by an X- ray powder diffraction pattern comprising peaks at 8.5, 12.8, 16.2, 21.6, 22.9, and 27.4° 20±0.2° 20; and having a unimodal particle distribution of D90 of about 21 pm to 29 pm, a D50 of about 12 pm to 17 pm, and a D10 of about 6 pm to 10 pm; and a pharmaceutically acceptable excipient comprising 42.6 mg of lactose monohydrate, 9.12 mg of microcrystalline cellulose, 3.6 mg of povidone K30, 4.0 mg of croscarmellose sodium and 0.68 mg of magnesium stearate; and the coating comprises 2.64 mg poly vinyl alcohol, 1.20 mg talc, 0.74 mg macrogol 3350, 0.28 mgtitanium dioxide, 0.58 mg Allura Red AC in aluminum lake 38-42%, 0.34 mg Allura Red AC in aluminum lake 15-17% and 0.21 mg lecithin.

[0079] In some embodiments, the medicament according to any embodiment described herein is a tablet comprising a tablet core and a coating wherein: the tablet core comprises 50 mg of roxadustat according to any embodiment described herein and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises Allura Red AC in aluminum lake and titanium dioxide. In some embodiments, the tablet core comprises lactose monohydrate, microcrystalline cellulose, povidone K30, croscarmellose sodium, and magnesium stearate. In some embodiments, the tablet core comprises 106.5 mg of lactose monohydrate, 22.8 mg of microcrystalline cellulose, 9.0 mg of povidone K30, 10 mg ofcroscarmellose sodium and 1.7 mg of magnesium stearate. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin. In some embodiments the coating comprises 0.1 to 0.4 mg / cm2titanium dioxide, and 0.1 -0.4 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. In some embodiments the coating comprises 0.285 mg / cm2titanium dioxide, and 0.278 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. In some embodiments the surface area of the tablet is 1.638 cm2. In some embodiments the coating comprises 0.285 mg / cm2titanium dioxide, and 0.278 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet and the surface area of the tablet is 1.638 cm2. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, 0.285 mg / cm2titanium dioxide based on surface area of the tablet, 0.278 mg / cm2Allura Red AC in aluminum lake based on surface are of the tablet, and lecithin; and the surface area of the tablet is 1.638 cm2. In some embodiments the coating comprises 4.84 mg poly vinyl alcohol, 2.20 mg talc, 1.36 mg macrogol 3350, 0.51 mgtitanium dioxide, 1.07 mg Allura Red AC in aluminum lake 38-42%, 0.63 mg Allura Red AC in aluminum lake 15- 17% and 0.39 mg lecithin. In some embodiments the tablet core comprises 106.5 mg of lactose monohydrate, 22.8 mg of microcrystalline cellulose, 9.0 mg of povidone K30, 10 mg of croscarmellose sodium and 1.7 mg of magnesium stearate and the coating comprises 4.84 mg poly vinyl alcohol, 2.20 mg talc, 1.36 mg macrogol 3350, 0.51 mgtitanium dioxide, 1.07 mg Allura Red AC in aluminum lake 38-42%, 0.63 mg Allura Red AC in aluminum lake 15- 17% and 0.39 mg lecithin.

[0080] In some embodiments, the medicament according to any embodiment described herein is a tablet comprising a tablet core and a coating wherein: the tablet comprises 50 mg of solid roxadustat wherein the solid roxadustat has a unimodal particle distribution of D90 of about 21 pm to 29 pm; a D50 of about 12 pm to 17 pm; and a D10 of about 6 pm to 10 pm; and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises Allura Red AC in aluminum lake and titanium dioxide. In some embodiments, the tablet core comprises lactose monohydrate, microcrystalline cellulose, povidone K30, croscarmellose sodium, and magnesium stearate. In some embodiments, the tablet core comprises 106.5 mg of lactose monohydrate, 22.8 mg of microcrystalline cellulose, 9.0 mg of povidone K30, 10 mg of croscarmellose sodium and 1.7 mg of magnesium stearate. In some embodiments the coating comprises poly vinyl alcohol, talc,macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin. In some embodiments the coating comprises 0.1 to 0.4 mg / cm2titanium dioxide, and 0.1-0.4 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. In some embodiments the coating comprises 0.285 mg / cm2titanium dioxide, and 0.278 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. In some embodiments the surface area of the tablet is 1.638 cm2. In some embodiments the coating comprises 0.285 mg / cm2titanium dioxide, and 0.278 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet and the surface area of the tablet is 1.638 cm2. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, 0.285 mg / cm2titanium dioxide based on surface area of the tablet, 0.278 mg / cm2Allura Red AC in aluminum lake based on surface are of the tablet, and lecithin; and the surface area of the tablet is 1.638 cm2. In some embodiments the coating comprises 4.84 mg poly vinyl alcohol, 2.20 mg talc, 1.36 mg macrogol 3350, 0.51 mg titanium dioxide, 1.07 mg Allura Red AC in aluminum lake 38-42%, 0.63 mg Allura Red AC in aluminum lake 15-17% and 0.39 mg lecithin. In some embodiments the tablet core comprises 106.5 mg of lactose monohydrate, 22.8 mg of microcrystalline cellulose, 9.0 mg of povidone K30, 10 mg of croscarmellose sodium and 1.7 mg of magnesium stearate and the coating comprises 4.84 mg poly vinyl alcohol, 2.20 mg talc, 1.36 mg macrogol 3350, 0.51 mg titanium dioxide, 1.07 mg Allura Red AC in aluminum lake 38-42%, 0.63 mg Allura Red AC in aluminum lake 15-17% and 0.39 mg lecithin.

[0081] In some embodiments, the medicament according to any embodiment described herein is a tablet comprising a tablet core and a coating wherein: the tablet core comprises 50 mg of solid roxadustat, wherein the roxadustat is roxadustat Form A characterized by an X- ray powder diffraction pattern comprising peaks at 8.5, 12.8, 16.2, 21.6, 22.9, and 27.4° 20±0.2° 20; and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises Allura Red AC in aluminum lake and titanium dioxide. In some embodiments, the tablet core comprises lactose monohydrate, microcrystalline cellulose, povidone K30, croscarmellose sodium, and magnesium stearate. In some embodiments, the tablet core comprises 106.5 mg of lactose monohydrate, 22.8 mg of microcrystalline cellulose, 9.0 mg of povidone K30, 10 mg of croscarmellose sodium and 1.7 mg of magnesium stearate. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin. In someembodiments the coating comprises 0.1 to 0.4 mg / cm2titanium dioxide, and 0.1-0.4 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. In some embodiments the coating comprises 0.285 mg / cm2titanium dioxide, and 0.278 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. In some embodiments the surface area of the tablet is 1.638 cm2. In some embodiments the coating comprises 0.285 mg / cm2titanium dioxide, and 0.278 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet and the surface area of the tablet is 1.638 cm2. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, 0.285 mg / cm2titanium dioxide based on surface area of the tablet, 0.278 mg / cm2Allura Red AC in aluminum lake based on surface are of the tablet, and lecithin; and the surface area of the tablet is 1.638 cm2. In some embodiments the coating comprises 4.84 mg poly vinyl alcohol, 2.20 mg talc, 1.36 mg macrogol 3350, 0.51 mg titanium dioxide, 1.07 mg Allura Red AC in aluminum lake 38-42%, 0.63 mg Allura Red AC in aluminum lake 15-17% and 0.39 mg lecithin. In some embodiments the tablet core comprises 106.5 mg of lactose monohydrate, 22.8 mg of microcrystalline cellulose, 9.0 mg of povidone K30, 10 mg of croscarmellose sodium and 1.7 mg of magnesium stearate and the coating comprises 4.84 mg poly vinyl alcohol, 2.20 mg talc, 1.36 mg macrogol 3350, 0.51 mg titanium dioxide, 1.07 mg Allura Red AC in aluminum lake 38-42%, 0.63 mg Allura Red AC in aluminum lake 15-17% and 0.39 mg lecithin.

[0082] In some embodiments, the medicament according to any embodiment described herein is a tablet comprising a tablet core and a coating wherein: the tablet core comprises 50 mg of solid roxadustat, wherein the roxadustat is roxadustat Form A characterized by an X- ray powder diffraction pattern comprising peaks at 8.5, 12.8, 16.2, 21.6, 22.9, and 27.4° 20±O.2° 20; and having a unimodal particle distribution of D90 of about 21 pm to 29 pm, a D50 of about 12 pm to 17 pm, and a D10 of about 6 pm to 10 pm; and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises Allura Red AC in aluminum lake and titanium dioxide. In some embodiments, the tablet core comprises lactose monohydrate, microcrystalline cellulose, povidone K30, croscarmellose sodium, and magnesium stearate. In some embodiments, the tablet core comprises 106.5 mg of lactose monohydrate, 22.8 mg of microcrystalline cellulose, 9.0 mg of povidone K30, 10 mg of croscarmellose sodium and 1.7 mg of magnesium stearate. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake,titanium dioxide and lecithin. In some embodiments the coating comprises 0.1 to 0.4 mg / cm2titanium dioxide, and 0.1 -0.4 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. In some embodiments the coating comprises 0.285 mg / cm2titanium dioxide, and 0.278 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. In some embodiments the surface area of the tablet is 1.638 cm2. In some embodiments the coating comprises 0.285 mg / cm2titanium dioxide, and 0.278 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet and the surface area of the tablet is 1.638 cm2. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, 0.285 mg / cm2titanium dioxide based on surface area of the tablet, 0.278 mg / cm2Allura Red AC in aluminum lake based on surface are of the tablet, and lecithin; and the surface area of the tablet is 1.638 cm2. In some embodiments the coating comprises 4.84 mg poly vinyl alcohol, 2.20 mg talc, 1.36 mg macrogol 3350, 0.51 mgtitanium dioxide, 1.07 mg Allura Red AC in aluminum lake 38-42%, 0.63 mg Allura Red AC in aluminum lake 15- 17% and 0.39 mg lecithin. In some embodiments the tablet core comprises 106.5 mg of lactose monohydrate, 22.8 mg of microcrystalline cellulose, 9.0 mg of povidone K30, 10 mg of croscarmellose sodium and 1.7 mg of magnesium stearate and the coating comprises 4.84 mg poly vinyl alcohol, 2.20 mg talc, 1.36 mg macrogol 3350, 0.51 mgtitanium dioxide, 1.07 mg Allura Red AC in aluminum lake 38-42%, 0.63 mg Allura Red AC in aluminum lake 15- 17% and 0.39 mg lecithin.

[0083] In some embodiments, the medicament according to any embodiment described herein is a tablet comprising a tablet core and a coating wherein: the tablet core comprises 50 mg of solid roxadustat, wherein the roxadustat is roxadustat Form A characterized by an X- ray powder diffraction pattern comprising peaks at 8.5, 12.8, 16.2, 21.6, 22.9, and 27.4° 20±0.2° 20; and having a unimodal particle distribution of D90 of about 21 pm to 29 pm, a D50 of about 12 pm to 17 pm, and a D10 of about 6 pm to 10 pm; and a pharmaceutically acceptable excipient comprising 106.5 mg of lactose monohydrate, 22.8 mg of microcrystalline cellulose, 9.0 mg of povidone K30, 10 mg of croscarmellose sodium and 1.7 mg of magnesium stearate; and the coating comprises 4.84 mg poly vinyl alcohol, 2.20 mg talc, 1.36 mg macrogol 3350, 0.51 mgtitanium dioxide, 1.07 mg Allura Red AC in aluminum lake 38-42%, 0.63 mg Allura Red AC in aluminum lake 15-17% and 0.39 mg lecithin.

[0084] In some embodiments, the medicament according to any embodiment described herein is a tablet comprising a tablet core and a coating wherein: the tablet core comprises 70 mg of roxadustat according to any embodiment described herein and a pharmaceuticallyacceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises Allura Red AC in aluminum lake and titanium dioxide. In some embodiments, the tablet core comprises lactose monohydrate, microcrystalline cellulose, povidone K30, croscarmellose sodium, and magnesium stearate. In some embodiments, the tablet core comprises 149.1 mg of lactose monohydrate, 31.92 mg of microcrystalline cellulose, 12.6 mg of povidone K30, 14 mg of croscarmellose sodium and 2.38 mg of magnesium stearate. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin. In some embodiments the coating comprises 0.1 to 0.4 mg / cm2titanium dioxide, and 0.1 -0.4 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. 0.295 mg / cm2titanium dioxide, and 0.288 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. In some embodiments the surface area of the tablet is 1.885 cm2. In some embodiments the coating comprises 0.295 mg / cm2titanium dioxide, and 0.288 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet and the surface area of the tablet is 1.885 cm2. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, 0.295 mg / cm2titanium dioxide based on surface area of the tablet, 0.288 mg / cm2Allura Red AC in aluminum lake based on surface are of the tablet, and lecithin; and the surface area of the tablet is 1.885 cm2. In some embodiments the coating comprises 5.85 mg poly vinyl alcohol, 2.66 mg talc, 1.64 mg macrogol 3350, 0.62 mg titanium dioxide, 1.30 mg Allura Red AC in aluminum lake 38-42%, 0.76 mg Allura Red AC in aluminum lake 15-17% and 0.47 mg lecithin. In some embodiments the tablet core comprises 149.1 mg of lactose monohydrate, 31.92 mg of microcrystalline cellulose, 12.6 mg of povidone K30, 14 mg of croscarmellose sodium and 2.38 mg of magnesium stearate and the coating comprises 5.85 mg poly vinyl alcohol, 2.66 mg talc, 1.64 mg macrogol 3350, 0.62 mg titanium dioxide, 1.30 mg Allura Red AC in aluminum lake 38-42%, 0.76 mg Allura Red AC in aluminum lake 15-17% and 0.47 mg lecithin.

[0085] In some embodiments, the medicament according to any embodiment described herein is a tablet comprising a tablet core and a coating wherein: the tablet comprises 70 mg of solid roxadustat wherein the solid roxadustat has a unimodal particle distribution of D90 of about 21 pm to 29 pm; a D50 of about 12 pm to 17 pm; and a D10 of about 6 pm to 10 pm; and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; andthe coating comprises Allura Red AC in aluminum lake and titanium dioxide. In some embodiments, the tablet core comprises lactose monohydrate, microcrystalline cellulose, povidone K30, croscarmellose sodium, and magnesium stearate. In some embodiments, the tablet core comprises 149.1 mg of lactose monohydrate, 31.92 mg of microcrystalline cellulose, 12.6 mg of povidone K30, 14 mg of croscarmellose sodium and 2.38 mg of magnesium stearate. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin. In some embodiments the coating comprises 0.1 to 0.4 mg / cm2titanium dioxide, and 0.1-0.4 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. 0.295 mg / cm2titanium dioxide, and 0.288 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. In some embodiments the surface area of the tablet is 1.885 cm2. In some embodiments the coating comprises 0.295 mg / cm2titanium dioxide, and 0.288 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet and the surface area of the tablet is 1.885 cm2. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, 0.295 mg / cm2titanium dioxide based on surface area of the tablet, 0.288 mg / cm2Allura Red AC in aluminum lake based on surface are of the tablet, and lecithin; and the surface area of the tablet is 1.885 cm2. In some embodiments the coating comprises 5.85 mg poly vinyl alcohol, 2.66 mg talc, 1.64 mg macrogol 3350, 0.62 mg titanium dioxide, 1.30 mg Allura Red AC in aluminum lake 38-42%, 0.76 mg Allura Red AC in aluminum lake 15- 17% and 0.47 mg lecithin. In some embodiments the tablet core comprises 149.1 mg of lactose monohydrate, 31.92 mg of microcrystalline cellulose, 12.6 mg of povidone K30, 14 mg of croscarmellose sodium and 2.38 mg of magnesium stearate and the coating comprises 5.85 mg poly vinyl alcohol, 2.66 mg talc, 1.64 mg macrogol 3350, 0.62 mgtitanium dioxide, 1.30 mg Allura Red AC in aluminum lake 38-42%, 0.76 mg Allura Red AC in aluminum lake 15-17% and 0.47 mg lecithin.

[0086] In some embodiments, the medicament according to any embodiment described herein is a tablet comprising a tablet core and a coating wherein: the tablet core comprises 70 mg of solid roxadustat, wherein the roxadustat is roxadustat Form A characterized by an X- ray powder diffraction pattern comprising peaks at 8.5, 12.8, 16.2, 21.6, 22.9, and 27.4° 20±0.2° 20; and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises Allura Red AC in aluminum lake and titanium dioxide. In some embodiments, the tablet core comprises lactose monohydrate, microcrystalline cellulose,povidone K30, croscarmellose sodium, and magnesium stearate. In some embodiments, the tablet core comprises 149.1 mg of lactose monohydrate, 31.92 mg of microcrystalline cellulose, 12.6 mg of povidone K30, 14 mg of croscarmellose sodium and 2.38 mg of magnesium stearate. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin. In some embodiments the coating comprises 0.1 to 0.4 mg / cm2titanium dioxide, and 0.1-0.4 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. 0.295 mg / cm2titanium dioxide, and 0.288 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. In some embodiments the surface area of the tablet is 1.885 cm2. In some embodiments the coating comprises 0.295 mg / cm2titanium dioxide, and 0.288 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet and the surface area of the tablet is 1.885 cm2. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, 0.295 mg / cm2titanium dioxide based on surface area of the tablet, 0.288 mg / cm2Allura Red AC in aluminum lake based on surface are of the tablet, and lecithin; and the surface area of the tablet is 1.885 cm2. In some embodiments the coating comprises 5.85 mg poly vinyl alcohol, 2.66 mg talc, 1.64 mg macrogol 3350, 0.62 mg titanium dioxide, 1.30 mg Allura Red AC in aluminum lake 38-42%, 0.76 mg Allura Red AC in aluminum lake 15- 17% and 0.47 mg lecithin. In some embodiments the tablet core comprises 149.1 mg of lactose monohydrate, 31.92 mg of microcrystalline cellulose, 12.6 mg of povidone K30, 14 mg of croscarmellose sodium and 2.38 mg of magnesium stearate and the coating comprises 5.85 mg poly vinyl alcohol, 2.66 mg talc, 1.64 mg macrogol 3350, 0.62 mgtitanium dioxide, 1.30 mg Allura Red AC in aluminum lake 38-42%, 0.76 mg Allura Red AC in aluminum lake 15-17% and 0.47 mg lecithin.

[0087] In some embodiments, the medicament according to any embodiment described herein is a tablet comprising a tablet core and a coating wherein: the tablet core comprises 70 mg of solid roxadustat, wherein the roxadustat is roxadustat Form A characterized by an X- ray powder diffraction pattern comprising peaks at 8.5, 12.8, 16.2, 21.6, 22.9, and 27.4° 20±0.2° 20; and having a unimodal particle distribution of D90 of about 21 pm to 29 pm, a D50 of about 12 pm to 17 pm, and a D10 of about 6 pm to 10 pm; and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises Allura Red AC in aluminum lake and titanium dioxide. In some embodiments, the tablet core comprises lactose monohydrate, microcrystalline cellulose, povidone K30, croscarmellose sodium, andmagnesium stearate. In some embodiments, the tablet core comprises 149.1 mg of lactose monohydrate, 31.92 mg of microcrystalline cellulose, 12.6 mg of povidone K30, 14 mg of croscarmellose sodium and 2.38 mg of magnesium stearate. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin. In some embodiments the coating comprises 0.1 to 0.4 mg / cm2titanium dioxide, and 0.1 -0.4 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. 0.295 mg / cm2titanium dioxide, and 0.288 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. In some embodiments the surface area of the tablet is 1.885 cm2. In some embodiments the coating comprises 0.295 mg / cm2titanium dioxide, and 0.288 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet and the surface area of the tablet is 1.885 cm2. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, 0.295 mg / cm2titanium dioxide based on surface area of the tablet, 0.288 mg / cm2Allura Red AC in aluminum lake based on surface are of the tablet, and lecithin; and the surface area of the tablet is 1.885 cm2. In some embodiments the coating comprises 5.85 mg poly vinyl alcohol, 2.66 mg talc, 1.64 mg macrogol 3350, 0.62 mg titanium dioxide, 1.30 mg Allura Red AC in aluminum lake 38-42%, 0.76 mg Allura Red AC in aluminum lake 15-17% and 0.47 mg lecithin. In some embodiments the tablet core comprises 149.1 mg of lactose monohydrate, 31.92 mg of microcrystalline cellulose, 12.6 mg of povidone K30, 14 mg of croscarmellose sodium and 2.38 mg of magnesium stearate and the coating comprises 5.85 mg poly vinyl alcohol, 2.66 mg talc, 1.64 mg macrogol 3350, 0.62 mg titanium dioxide, 1.30 mg Allura Red AC in aluminum lake 38-42%, 0.76 mg Allura Red AC in aluminum lake 15-17% and 0.47 mg lecithin.

[0088] In some embodiments, the medicament according to any embodiment described herein is a tablet comprising a tablet core and a coating wherein: the tablet core comprises 70 mg of solid roxadustat, wherein the roxadustat is roxadustat Form A characterized by an X- ray powder diffraction pattern comprising peaks at 8.5, 12.8, 16.2, 21.6, 22.9, and 27.4° 20±0.2° 20; and having a unimodal particle distribution of D90 of about 21 pm to 29 pm, a D50 of about 12 pm to 17 pm, and a D10 of about 6 pm to 10 pm; and a pharmaceutically acceptable excipient comprising 149.1 mg of lactose monohydrate, 31.92 mg of microcrystalline cellulose, 12.6 mg of povidone K30, 14 mg of croscarmellose sodium and 2.38 mg of magnesium stearate; and the coating comprises 2.64 mg poly vinyl alcohol, 1.20 mg talc, 0.74 mg macrogol 3350, 0.28 mgtitanium dioxide, 0.58 mg Allura Red AC inaluminum lake 38-42%, 0.34 mg Allura Red AC in aluminum lake 15-17% and 0.21 mg lecithin.

[0089] In some embodiments, the medicament according to any embodiment described herein is a tablet comprising a tablet core and a coating wherein: the tablet core comprises 100 mg of roxadustat according to any embodiment described herein and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises Allura Red AC in aluminum lake and titanium dioxide. In some embodiments, the tablet core comprises lactose monohydrate, microcrystalline cellulose, povidone K30, croscarmellose sodium, and magnesium stearate. In some embodiments, the tablet core comprises 213.0 mg of lactose monohydrate, 45.6 mg of microcrystalline cellulose, 18.0 mg of povidone K30, 20 mg of croscarmellose sodium and 3.4 mg of magnesium stearate. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin. In some embodiments the coating comprises 0.1 to 0.4 mg / cm2titanium dioxide, and 0.1 -0.4 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. In some embodiments the coating comprises 0.295 mg / cm2titanium dioxide, and 0.288 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. In some embodiments the surface area of the tablet is 2.535 cm2. In some embodiments the coating comprises 0.295 mg / cm2titanium dioxide, and 0.288 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet and the surface area of the tablet is 2.535 cm2. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, 0.295 mg / cm2titanium dioxide based on surface area of the tablet, 0.288 mg / cm2Allura Red AC in aluminum lake based on surface are of the tablet, and lecithin; and the surface area of the tablet is 2.535 cm2. In some embodiments the coating comprises 7.92 mg poly vinyl alcohol, 3.6 mg talc, 2.22 mg macrogol 3350, 0.84 mg titanium dioxide, 1.75 mg Allura Red AC in aluminum lake 38-42%, 1.03 mg Allura Red AC in aluminum lake 15- 17% and 0.63 mg lecithin. In some embodiments the tablet core comprises 213.0 mg of lactose monohydrate, 45.6 mg of microcrystalline cellulose, 18.0 mg of povidone K30, 20 mg of croscarmellose sodium and 3.4 mg of magnesium stearate and the coating comprises 7.92 mg poly vinyl alcohol, 3.6 mg talc, 2.22 mg macrogol 3350, 0.84 mg titanium dioxide, 1.75 mg Allura Red AC in aluminum lake 38-42%, 1.03 mg Allura Red AC in aluminum lake 15- 17% and 0.63 mg lecithin.

[0090] In some embodiments, the medicament according to any embodiment described herein is a tablet comprising a tablet core and a coating wherein: the tablet comprises 100 mg of solid roxadustat wherein the solid roxadustat has a unimodal particle distribution of D90 of about 21 pm to 29 pm; a D50 of about 12 pm to 17 pm; and a D10 of about 6 pm to 10 pm; and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises Allura Red AC in aluminum lake and titanium dioxide. In some embodiments, the tablet core comprises lactose monohydrate, microcrystalline cellulose, povidone K30, croscarmellose sodium, and magnesium stearate. In some embodiments, the tablet core comprises 213.0 mg of lactose monohydrate, 45.6 mg of microcrystalline cellulose, 18.0 mg of povidone K30, 20 mg of croscarmellose sodium and 3.4 mg of magnesium stearate. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin. In some embodiments the coating comprises 0.1 to 0.4 mg / cm2titanium dioxide, and 0.1-0.4 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. In some embodiments the coating comprises 0.295 mg / cm2titanium dioxide, and 0.288 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. In some embodiments the surface area of the tablet is 2.535 cm2. In some embodiments the coating comprises 0.295 mg / cm2titanium dioxide, and 0.288 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet and the surface area of the tablet is 2.535 cm2. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, 0.295 mg / cm2titanium dioxide based on surface area of the tablet, 0.288 mg / cm2Allura Red AC in aluminum lake based on surface are of the tablet, and lecithin; and the surface area of the tablet is 2.535 cm2. In some embodiments the coating comprises 7.92 mg poly vinyl alcohol,3.6 mg talc, 2.22 mg macrogol 3350, 0.84 mg titanium dioxide, 1.75 mg Allura Red AC in aluminum lake 38-42%, 1.03 mg Allura Red AC in aluminum lake 15-17% and 0.63 mg lecithin. In some embodiments the tablet core comprises 213.0 mg of lactose monohydrate,45.6 mg of microcrystalline cellulose, 18.0 mg of povidone K30, 20 mg of croscarmellose sodium and 3.4 mg of magnesium stearate and the coating comprises 7.92 mg poly vinyl alcohol, 3.6 mg talc, 2.22 mg macrogol 3350, 0.84 mgtitanium dioxide, 1.75 mgAllura Red AC in aluminum lake 38-42%, 1.03 mgAllura Red AC in aluminum lake 15-17% and 0.63 mg lecithin.

[0091] In some embodiments, the medicament according to any embodiment described herein is a tablet comprising a tablet core and a coating wherein: the tablet core comprises 100 mg of solid roxadustat, wherein the roxadustat is roxadustat Form A characterized by an X-ray powder diffraction pattern comprising peaks at 8.5, 12.8, 16.2, 21.6, 22.9, and 27.4° 20±0.2° 20; and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises Allura Red AC in aluminum lake and titanium dioxide. In some embodiments, the tablet core comprises lactose monohydrate, microcrystalline cellulose, povidone K30, croscarmellose sodium, and magnesium stearate. In some embodiments, the tablet core comprises 213.0 mg of lactose monohydrate, 45.6 mg of microcrystalline cellulose, 18.0 mg of povidone K30, 20 mg of croscarmellose sodium and 3.4 mg of magnesium stearate. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin. In some embodiments the coating comprises 0.1 to 0.4 mg / cm2titanium dioxide, and 0.1-0.4 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. In some embodiments the coating comprises 0.295 mg / cm2titanium dioxide, and 0.288 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. In some embodiments the surface area of the tablet is 2.535 cm2. In some embodiments the coating comprises 0.295 mg / cm2titanium dioxide, and 0.288 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet and the surface area of the tablet is 2.535 cm2. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, 0.295 mg / cm2titanium dioxide based on surface area of the tablet, 0.288 mg / cm2Allura Red AC in aluminum lake based on surface are of the tablet, and lecithin; and the surface area of the tablet is 2.535 cm2. In some embodiments the coating comprises 7.92 mg poly vinyl alcohol,3.6 mg talc, 2.22 mg macrogol 3350, 0.84 mg titanium dioxide, 1.75 mg Allura Red AC in aluminum lake 38-42%, 1.03 mg Allura Red AC in aluminum lake 15-17% and 0.63 mg lecithin. In some embodiments the tablet core comprises 213.0 mg of lactose monohydrate,45.6 mg of microcrystalline cellulose, 18.0 mg of povidone K30, 20 mg of croscarmellose sodium and 3.4 mg of magnesium stearate and the coating comprises 7.92 mg poly vinyl alcohol, 3.6 mg talc, 2.22 mg macrogol 3350, 0.84 mgtitanium dioxide, 1.75 mgAllura Red AC in aluminum lake 38-42%, 1.03 mgAllura Red AC in aluminum lake 15-17% and 0.63 mg lecithin.

[0092] In some embodiments, the medicament according to any embodiment described herein is a tablet comprising a tablet core and a coating wherein: the tablet core comprises 100 mg of solid roxadustat, wherein the roxadustat is roxadustat Form A characterized by an X-ray powder diffraction pattern comprising peaks at 8.5, 12.8, 16.2, 21.6, 22.9, and 27.4° 20±0.2° 20; and having a unimodal particle distribution of D90 of about 21 pm to 29 pm, a D50 of about 12 pm to 17 pm, and a D10 of about 6 pm to 10 pm; and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises Allura Red AC in aluminum lake and titanium dioxide. In some embodiments, the tablet core comprises lactose monohydrate, microcrystalline cellulose, povidone K30, croscarmellose sodium, and magnesium stearate. In some embodiments, the tablet core comprises 213.0 mg of lactose monohydrate, 45.6 mg of microcrystalline cellulose, 18.0 mg of povidone K30, 20 mg of croscarmellose sodium and 3.4 mg of magnesium stearate. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin. In some embodiments the coating comprises 0.1 to 0.4 mg / cm2titanium dioxide, and 0.1 -0.4 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. In some embodiments the coating comprises 0.295 mg / cm2titanium dioxide, and 0.288 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. In some embodiments the surface area of the tablet is 2.535 cm2. In some embodiments the coating comprises 0.295 mg / cm2titanium dioxide, and 0.288 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet and the surface area of the tablet is 2.535 cm2. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, 0.295 mg / cm2titanium dioxide based on surface area of the tablet, 0.288 mg / cm2Allura Red AC in aluminum lake based on surface are of the tablet, and lecithin; and the surface area of the tablet is 2.535 cm2. In some embodiments the coating comprises 7.92 mg poly vinyl alcohol, 3.6 mg talc, 2.22 mg macrogol 3350, 0.84 mg titanium dioxide, 1.75 mg Allura Red AC in aluminum lake 38-42%, 1.03 mg Allura Red AC in aluminum lake 15- 17% and 0.63 mg lecithin. In some embodiments the tablet core comprises 213.0 mg of lactose monohydrate, 45.6 mg of microcrystalline cellulose, 18.0 mg of povidone K30, 20 mg of croscarmellose sodium and 3.4 mg of magnesium stearate and the coating comprises 7.92 mg poly vinyl alcohol, 3.6 mg talc, 2.22 mg macrogol 3350, 0.84 mg titanium dioxide, 1.75 mg Allura Red AC in aluminum lake 38-42%, 1.03 mg Allura Red AC in aluminum lake 15- 17% and 0.63 mg lecithin.

[0093] In some embodiments, the medicament according to any embodiment described herein is a tablet comprising a tablet core and a coating wherein: the tablet core comprises 100 mg of solid roxadustat, wherein the roxadustat is roxadustat Form A characterized by an X-ray powder diffraction pattern comprising peaks at 8.5, 12.8, 16.2, 21.6, 22.9, and 27.4° 20±O.2° 20; and having a unimodal particle distribution of D90 of about 21 pm to 29 pm, a D50 of about 12 pm to 17 pm, and a D10 of about 6 pm to 10 pm; and a pharmaceutically acceptable excipient comprising 213.0 mg of lactose monohydrate, 45.6 mg of microcrystalline cellulose, 18.0 mg of povidone K30, 20 mg of croscarmellose sodium and 3.4 mg of magnesium stearate; and the coating comprises 7.92 mg poly vinyl alcohol, 3.6 mg talc, 2.22 mg macrogol 3350, 0.84 mgtitanium dioxide, 1.75 mg Allura Red AC in aluminum lake 38-42%, 1.03 mg Allura Red AC in aluminum lake 15-17% and 0.63 mg lecithin.

[0094] In some embodiments, the medicament according to any embodiment described herein is a tablet comprising a tablet core and a coating wherein: the tablet core comprises 150 mg of roxadustat according to any embodiment described herein and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises Allura Red AC in aluminum lake and titanium dioxide. In some embodiments, the tablet core comprises lactose monohydrate, microcrystalline cellulose, povidone K30, croscarmellose sodium, and magnesium stearate, n some embodiments, the tablet core comprises lactose monohydrate, microcrystalline cellulose, povidone K30, croscarmellose sodium, and magnesium stearate. In some embodiments, the tablet core comprises 319.5 mg of lactose monohydrate, 68.4 mg of microcrystalline cellulose, 27.0 mg of povidone K30, 30 mg of croscarmellose sodium and 5.1 mg of magnesium stearate. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin. In some embodiments the coating comprises 0.1 to 0.4 mg / cm2titanium dioxide, and 0.1 -0.4 mg / cm2Allura Red AC in aluminum lake based, on the surface area of the tablet. In some embodiments the coating comprises 0.311 mg / cm2titanium dioxide, and 0.304 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. In some embodiments the surface area of the tablet is 3.156 cm2. In some embodiments the coating comprises 0.311 mg / cm2titanium dioxide, and 0.304 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet and the surface area of the tablet is 3.156 cm2. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, 0.311 mg / cm2titanium dioxide based on surface area of the tablet, 0.304 mg / cm2Allura Red AC inaluminum lake based on surface are of the tablet, and lecithin; and the surface area of the tablet is 3.156 cm2. In some embodiments the coating comprises 10.56 mg poly vinyl alcohol, 4.8 mg talc, 2.96 mg macrogol 3350, 1.12 mg titanium dioxide, 2.34 mg Allura Red AC in aluminum lake 38-42%, 1.38 mg Allura Red AC in aluminum lake 15-17% and 0.84 mg lecithin. In some embodiments the tablet core comprises 319.5 mg of lactose monohydrate, 68.4 mg of microcrystalline cellulose, 27.0 mg of povidone K30, 30 mg of croscarmellose sodium and 5.1 mg of magnesium stearate and the coating comprises 10.56 mg poly vinyl alcohol, 4.8 mg talc, 2.96 mg macrogol 3350, 1.12 mg titanium dioxide, 2.34 mg Allura Red AC in aluminum lake 38-42%, 1.38 mg Allura Red AC in aluminum lake 15-17% and 0.84 mg lecithin.

[0095] In some embodiments, the medicament according to any embodiment described herein is a tablet comprising a tablet core and a coating wherein: the tablet comprises 150 mg of solid roxadustat wherein the solid roxadustat has a unimodal particle distribution of D90 of about 21 pm to 29 pm; a D50 of about 12 pm to 17 pm; and a D10 of about 6 pm to 10 pm; and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises Allura Red AC in aluminum lake and titanium dioxide. In some embodiments, the tablet core comprises lactose monohydrate, microcrystalline cellulose, povidone K30, croscarmellose sodium, and magnesium stearate. In some embodiments, the tablet core comprises 319.5 mg of lactose monohydrate, 68.4 mg of microcrystalline cellulose, 27.0 mg of povidone K30, 30 mg of croscarmellose sodium and 5.1 mg of magnesium stearate. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin. In some embodiments the coating comprises 0.1 to 0.4 mg / cm2titanium dioxide, and 0.1-0.4 mg / cm2Allura Red AC in aluminum lake based, on the surface area of the tablet. In some embodiments the coating comprises 0.311 mg / cm2titanium dioxide, and 0.304 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. In some embodiments the surface area of the tablet is 3.156 cm2. In some embodiments the coating comprises 0.311 mg / cm2titanium dioxide, and 0.304 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet and the surface area of the tablet is 3.156 cm2. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, 0.311 mg / cm2titanium dioxide based on surface area of the tablet, 0.304 mg / cm2Allura Red AC in aluminum lake based on surface are of the tablet, and lecithin; and the surface area of thetablet is 3.156 cm2. In some embodiments the coating comprises 10.56 mg poly vinyl alcohol, 4.8 mg talc, 2.96 mg macrogol 3350, 1.12 mg titanium dioxide, 2.34 mg Allura Red AC in aluminum lake 38-42%, 1.38 mg Allura Red AC in aluminum lake 15-17% and 0.84 mg lecithin. In some embodiments the tablet core comprises 319.5 mg of lactose monohydrate, 68.4 mg of microcrystalline cellulose, 27.0 mg of povidone K30, 30 mg of croscarmellose sodium and 5.1 mg of magnesium stearate and the coating comprises 10.56 mg poly vinyl alcohol, 4.8 mg talc, 2.96 mg macrogol 3350, 1.12 mg titanium dioxide, 2.34 mg Allura Red AC in aluminum lake 38-42%, 1.38 mg Allura Red AC in aluminum lake 15-17% and 0.84 mg lecithin.

[0096] In some embodiments, the medicament according to any embodiment described herein is a tablet comprising a tablet core and a coating wherein: the tablet core comprises 150 mg of solid roxadustat, wherein the roxadustat is roxadustat Form A characterized by an X-ray powder diffraction pattern comprising peaks at 8.5, 12.8, 16.2, 21.6, 22.9, and 27.4° 20±0.2° 20; and a pharmaceutically acceptable excipient c comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises Allura Red AC in aluminum lake and titanium dioxide. In some embodiments, the tablet core comprises lactose monohydrate, microcrystalline cellulose, povidone K30, croscarmellose sodium, and magnesium stearate. In some embodiments, the tablet core comprises 319.5 mg of lactose monohydrate, 68.4 mg of microcrystalline cellulose, 27.0 mg of povidone K30, 30 mg of croscarmellose sodium and 5.1 mg of magnesium stearate. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin. In some embodiments the coating comprises 0.1 to 0.4 mg / cm2titanium dioxide, and 0.1-0.4 mg / cm2Allura Red AC in aluminum lake based, on the surface area of the tablet. In some embodiments the coating comprises 0.311 mg / cm2titanium dioxide, and 0.304 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. In some embodiments the surface area of the tablet is 3.156 cm2. In some embodiments the coating comprises 0.311 mg / cm2titanium dioxide, and 0.304 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet and the surface area of the tablet is 3.156 cm2. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, 0.311 mg / cm2titanium dioxide based on surface area of the tablet, 0.304 mg / cm2Allura Red AC in aluminum lake based on surface are of the tablet, and lecithin; and the surface area of the tablet is 3.156 cm2. In some embodiments the coating comprises 10.56 mg poly vinyl alcohol,4.8 mg talc, 2.96 mg macrogol 3350, 1.12 mg titanium dioxide, 2.34 mg Allura Red AC in aluminum lake 38-42%, 1.38 mg Allura Red AC in aluminum lake 15-17% and 0.84 mg lecithin. In some embodiments the tablet core comprises 319.5 mg of lactose monohydrate, 68.4 mg of microcrystalline cellulose, 27.0 mg of povidone K30, 30 mg of croscarmellose sodium and 5.1 mg of magnesium stearate and the coating comprises 10.56 mg poly vinyl alcohol, 4.8 mg talc, 2.96 mg macrogol 3350, 1.12 mg titanium dioxide, 2.34 mg Allura Red AC in aluminum lake 38-42%, 1.38 mg Allura Red AC in aluminum lake 15-17% and 0.84 mg lecithin.

[0097] In some embodiments, the medicament according to any embodiment described herein is a tablet comprising a tablet core and a coating wherein: the tablet core comprises 150 mg of solid roxadustat, wherein the roxadustat is roxadustat Form A characterized by an X-ray powder diffraction pattern comprising peaks at 8.5, 12.8, 16.2, 21.6, 22.9, and 27.4° 20±0.2° 20; and having a unimodal particle distribution of D90 of about 21 pm to 29 pm, a D50 of about 12 pm to 17 pm, and a D10 of about 6 pm to 10 pm; and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises Allura Red AC in aluminum lake and titanium dioxide. In some embodiments, the tablet core comprises lactose monohydrate, microcrystalline cellulose, povidone K30, croscarmellose sodium, and magnesium stearate. In some embodiments, the tablet core comprises 319.5 mg of lactose monohydrate, 68.4 mg of microcrystalline cellulose, 27.0 mg of povidone K30, 30 mg of croscarmellose sodium and 5.1 mg of magnesium stearate. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin. In some embodiments the coating comprises 0.1 to 0.4 mg / cm2titanium dioxide, and 0.1-0.4 mg / cm2Allura Red AC in aluminum lake based, on the surface area of the tablet. In some embodiments the coating comprises 0.311 mg / cm2titanium dioxide, and 0.304 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet. In some embodiments the surface area of the tablet is 3.156 cm2. In some embodiments the coating comprises 0.311 mg / cm2titanium dioxide, and 0.304 mg / cm2Allura Red AC in aluminum lake, based on the surface area of the tablet and the surface area of the tablet is 3.156 cm2. In some embodiments the coating comprises poly vinyl alcohol, talc, macrogol 3350, 0.311 mg / cm2titanium dioxide based on surface area of the tablet, 0.304 mg / cm2Allura Red AC in aluminum lake based on surface are of the tablet, and lecithin; and the surface area of the tablet is 3.156 cm2. In some embodiments the coating comprises 10.56mg poly vinyl alcohol, 4.8 mg talc, 2.96 mg macrogol 3350, 1.12 mg titanium dioxide, 2.34 mg Allura Red AC in aluminum lake 38-42%, 1.38 mg Allura Red AC in aluminum lake 15- 17% and 0.84 mg lecithin. In some embodiments the tablet core comprises 319.5 mg of lactose monohydrate, 68.4 mg of microcrystalline cellulose, 27.0 mg of povidone K30, 30 mg of croscarmellose sodium and 5.1 mg of magnesium stearate and the coating comprises 10.56 mg poly vinyl alcohol, 4.8 mg talc, 2.96 mg macrogol 3350, 1.12 mg titanium dioxide, 2.34 mg Allura Red AC in aluminum lake 38-42%, 1.38 mg Allura Red AC in aluminum lake 15- 17% and 0.84 mg lecithin.

[0098] In some embodiments, the medicament according to any embodiment described herein is a tablet comprising a tablet core and a coating wherein: the tablet core comprises 150 mg of solid roxadustat, wherein the roxadustat is roxadustat Form A characterized by an X-ray powder diffraction pattern comprising peaks at 8.5, 12.8, 16.2, 21.6, 22.9, and 27.4° 20±0.2° 20; and having a unimodal particle distribution of D90 of about 21 pm to 29 pm, a D50 of about 12 pm to 17 pm, and a D10 of about 6 pm to 10 pm; and a pharmaceutically acceptable excipient comprising 319.5 mg of lactose monohydrate, 68.4 mg of microcrystalline cellulose, 27.0 mg of povidone K30, 30 mg of croscarmellose sodium and 5.1 mg of magnesium stearate.; and the coating comprises 10.56 mg poly vinyl alcohol, 4.8 mg talc, 2.96 mg macrogol 3350, 1.12 mgtitanium dioxide, 2.34 mg Allura Red AC in aluminum lake 38-42%, 1.38 mg Allura Red AC in aluminum lake 15-17% and 0.84 mg lecithin.

[0099] Subjects

[0100] In some embodiments, a subject according to any embodiment described herein, is a patient who is undergoing chemotherapy and who has anemia related to chemotherapy treatment. In some embodiments the subject according to any embodiment described herein has been diagnosed with a non-myeloid malignancy and the anemia is related to myelosuppressive chemotherapy. In some embodiments the subject according to any embodiment described herein has a hemoglobin level <100 g / L prior to roxadustat treatment. In some embodiments, the subject according to any embodiment described herein has a hemoglobin level <100 g / L prior to roxadustat treatment, and the subject’s blood hemoglobin level decreased at least 10 g / L after the initiation of chemotherapy.

[0101] In some embodiments, the subject according to any embodiment described herein has a transferrin saturation (TSAT) >20% and ferritin >100 ng / mL prior to roxadustattreatment. In some embodiments, the subject according to any embodiment described herein has C-reactive protein (CRP) level < ULN (upper limit of normal) prior to roxadustat treatment. In some embodiments, the subject according to any embodiment described herein has a TSAT >20%, ferritin >100 ng / mL, and a CRP < ULN prior to roxadustat treatment. In some embodiments, the subject according to any embodiment described herein has a serum erythropoietin (Epo) level >200 U / L prior to roxadustat treatment. In some embodiments, the subject according to any embodiment described herein has an estimated glomerular filtration rate (eGFR) >60 mL / min / 1.73m2prior to roxadustat treatment. In some embodiments, the subject according to any embodiment described herein has an Epo level >200 U / L and eGFR >60 mL / min / 1.73m2prior to roxadustat treatment. In some embodiments, the subject according to any embodiment described herein has an Epo level >200 U / L, eGFR >60 mL / min / 1.73m2, TSAT >20%, ferritin >100 ng / mL, and a CRP < ULN prior to roxadustat treatment.

[0102] In some embodiments the subject according to any embodiment described herein is >18 years old. In some embodiments, the subject according to any embodiment described herein weighs >40 kg. In some embodiments, the subject according to any embodiment described herein has an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0, 1, or 2. In some embodiments, the subject according to any embodiment described herein has an estimated life expectancy >6 months at the beginning of roxadustat treatment.

[0103] In some embodiments, the subject according to any embodiment described herein has one or more of the preceding conditions. In some embodiments, the subject according to any embodiment described herein has two or more of the preceding conditions. In some embodiments, the subject according to any embodiment described herein has three or more of the preceding conditions. In some embodiments, the subject according to any embodiment described herein has four or more of the preceding conditions. In some embodiments, the subject according to any embodiment described herein has five or more of the preceding conditions. In some embodiments, the subject according to any embodiment described herein has six or more of the preceding conditions. In some embodiments, the subject according to any embodiment described herein has seven or more of the preceding conditions. In some embodiments, the subject according to any embodiment described herein has eight or more of the preceding conditions. In some embodiments, the subject according to any embodiment described herein has all of the preceding conditions.

[0104] In some embodiments, the subject according to any embodiment described herein is a patient who:• is more than 18 years old;• weighs more than 40 kg;• has a diagnosis of non-myeloid malignancy;• has an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0, 1, or 2;• has an estimated life expectancy >6 months prior to treatment with roxadustat; and• has anemia related to myelosuppressive chemotherapy (defined as Hb <100 g / L) prior to treatment with roxadustat, and the subject’s blood hemoglobin level decreased at least 10 g / L after the initiation of chemotherapy.

[0105] In some embodiments, the subject according to any embodiment described herein is a patient who, prior to roxadustat treatment:• has an Epo level >200 U / L,• has a TSAT >20%,• has a ferritin >100 ng / mL ,• has a CRP < ULN, and• has anemia related to myelosuppressive chemotherapy (defined as Hb <100 g / L) prior to treatment with roxadustat, and the subject’s blood hemoglobin level decreased at least 10 g / L after the initiation of chemotherapy.

[0106] In some embodiments of the invention, the blood hemoglobin level in the subject is increased following administration of roxadustat compared with the subject’s hemoglobin level prior to administration of roxadustat. In some embodiments of the invention, the subject reaches and maintains a hemoglobin level of >100 g / L for the remaining duration of treatment with roxadustat. In some embodiments, the subject reaches a hemoglobin level of >100 g / L 5-9 weeks following initiation of treatment and maintains a hemoglobin level of >100 g / L for the remaining duration of treatment. In some embodiments, the subject reaches and maintains a hemoglobin level of >100 g / L up to 130 g / L during treatment.

[0107] Chemotherapies and non-myeloid malignancies

[0108] In some embodiments, the chemotherapeutic agent according to any embodiment described herein is a myelosuppressive chemotherapeutic agent. In some embodiments, the chemotherapeutic agent according to any embodiment described herein is a platinum ornonplatinum chemotherapeutic agent. In some embodiments, the chemotherapeutic agent according to any embodiment described herein is a platinum chemotherapeutic agent. In some embodiments, the chemotherapeutic agent according to any embodiment described herein, is a platinum chemotherapeutic agent selected from the group comprising cisplatin, carboplatin, dicycloplatin, oxaliplatin, nedaplatin, and satraplatin. In some embodiments, the chemotherapeutic agent according to any embodiment described herein is a nonplatinum chemotherapeutic agent. In some embodiments, the chemotherapeutic agent according to any embodiment described herein is a nonplatinum chemotherapeutic agent selected from the group consisting of abraxane, actinomycin, alitretinoin, all-trans retinoic acid, altretamine, azacitidine, azathioprine, belotecan, bendamustine, bexarotene, bleomycin, bortezomib, busulfan, cabazitaxel, camptothecin, carboquone, carmustine, capecitabine, chlorambucil, chlormethine, chlorozotocin, cyclophosphamide, cytarabine, dacarbazine, daunorubicin, docetaxel, doxifluridine, doxorubicin, epirubicin, epothilone, erlotinib, etoposide, exatecan, fluorouracil, fotemustine, gefitinib, gemcitabine, gimatecan, hydroxyurea, idarubicin, ifosfamide, imatinib, irinotecan, ixabepilone, larotaxel, lomustine, melphalan, melphalan flufenamide, mercaptopurine, methotrexate, mitobronitol, mitomycin C, mitoxantrone, nimustine, nitrosoureas, paclitaxel, pemetrexed, pipobroman, panimustine, pomidepsin, pemustine, streptozotocin, tafluposide, taxotere, temozolomide, tesetaxel, teniposide, thiotepa, tioguanine, topotecan, treosulfan, tretinoin, triaziquone, triethylenemelamine, valrubicin, vemurafenib, vinblastine, vincristine, vindesine, vinorelbine, vismodegib, and vorinostat.

[0109] In some embodiments, other chemotherapeutic agents may be additionally used wherein the class of chemotherapeutic agents are selected from the group consisting of an antimetabolite, a plant alkaloid or other natural product, an alkylating agent, a cytotoxic antibiotic and related substance, a hormone antagonist, a monoclonal antibody or antibody drug conjugate, a drug affecting bone structure and mineralization, a protein kinase inhibitor and other neoplastic chemotherapeutic agents. In some embodiments, the chemotherapeutic agent according to any embodiment described herein is selected from the group consisting of abemaciclib, astragalus mongholicus root, atezolizumab, bevacizumab, calcium folinate, calcium levofolinate, camrelizumab, capecitabine, carboplatin, catequentinib, catequentinib hydrochloride, cetuximab, cisplatin, cyclophosphamide, denosumab, disodium cantharidinate, docetaxel, durvalumab, eleutherococcus senticosus root with rhizome, endostatin, envafolimab, epirubicin hydrochloride, eribulin, eribulin mesilate, etoposide, fluorouracil,fulvestrant, gefitinib, gemcitabine, gemcitabine hydrochloride, gimeracil , inetetamab, irinotecan, irinotecan hydrochloride, liposomal doxorubicin, lobaplatin, mylabris spp., nedaplatin, oteracil potassium, oxaliplatin, paclitaxel, paclitaxel liposome, paclitaxel nanoparticle albumin-bound, panax ginseng root, pegaspargase, pembrolizumab, pemetrexed, pemetrexed disodium, pemetrexed disodium heptahydrate, penpulimab, pyridoxine hydrochloride, pyrotinib maleate, rivoceranib mesylate, sintilimab, tamoxifen, tegafur, tislelizumab, toripalimab, and vinorelbine tartrate.

[0110] In some embodiments, the chemotherapeutic agent according to any embodiment described herein is for the treatment of a non-myeloid cancer. In some embodiments, the chemotherapeutic agent according to any embodiment described herein is for the treatment of lung cancer, breast cancer, head and neck cancer, gastrointestinal malignancies, gynecological malignancies, lymphoma, metastases, bile duct cancer, mesothelioma malignant, esophageal carcinoma, esophageal squamous cell carcinoma, and / or pancreatic carcinoma. In some embodiments, the chemotherapeutic agent according to any embodiment described herein is for the treatment of breast cancer, lung cancer, gastrointestinal cancer, gynecological cancer, pancreatic cancer, and / or head and neck cancer.[OHl] In some embodiments, the chemotherapeutic agent according to any embodiment described herein is for the treatment of adenocarcinoma gastric, adenocarcinoma of the cervix, adenolymphoma, angiocentric lymphoma, bile duct cancer, bladder transitional cell carcinoma, breast cancer, cervix carcinoma, colon cancer, diffuse large B-cell lymphoma, endometrial cancer, gastric cancer, hepatobiliary cancer, invasive breast carcinoma, invasive ductal breast carcinoma, keratinizing squamous cell carcinoma of nasopharynx, lung adenocarcinoma, lung adenocarcinoma stage IV, lung neoplasm malignant, lung squamous cell carcinoma stage IV, mesothelioma malignant, metastases to abdominal cavity, metastases to adrenals, metastases to bone, metastases to central nervous system, metastases to chest wall, metastases to heart, metastases to liver, metastases to lung, metastases to lymph nodes, metastases to pancreas, metastases to pelvis, metastases to peritoneum, metastases to pharynx, metastases to pleura, metastases to spine, metastases to spleen, nasopharyngeal cancer, neuroendocrine tumor of the lung, esophageal carcinoma, esophageal squamous cell carcinoma, ovarian cancer, ovarian cancer stage III, pancreatic carcinoma, papillary thyroid cancer, peritoneal mesothelioma malignant rectal cancer, sarcomatoid carcinoma of the lung, small cell lung cancer, squamous cell carcinoma of lung, squamous cell carcinoma of the tongue, throat cancer, and / or uterine cancer.

[0112] The roxadustat medicament may be initiated at any point during the course of chemotherapy. For example, the roxadustat medicament may be initiated during the treatment period of a chemotherapy cycle, during a rest period of a chemotherapy cycle, or during both a treatment and rest period of a chemotherapy cycle. The roxadustat medicament may be administered during any cycle of a chemotherapy course, in more than one cycle of a chemotherapy course, or in all the cycles of a chemotherapy course. The roxadustat medicament may be administered at the outset of a chemotherapy cycle.

[0113] Dose

[0114] A therapeutically effective dose of roxadustat medicament, according to any embodiment described herein, refers to that amount that results in the subject achieving a hemoglobin level of >110 g / L. In some embodiments, a therapeutically effective dose refers to that amount that results in the subject achieving a hemoglobin level of >110 g / L to 130 g / L. In some embodiments, a therapeutically effective dose refers to that amount that results in the subject achieving a hemoglobin level of 100 to 130 g / L. In some embodiments, a therapeutically effective dose refers to that amount that results in the subject achieving a hemoglobin level of >100 g / L to 120 g / L.

[0115] In some embodiments, a therapeutically effective dose of roxadustat medicament, according to any embodiment described herein, refers to that amount that results in an increase in the subject’s hemoglobin level, compared with the hemoglobin level prior to treatment. In some embodiments, a therapeutically effective dose refers to that amount that results in a >10 g / L increase in the subject’s hemoglobin level, compared with the hemoglobin level prior to treatment. In some embodiments, a therapeutically effective dose refers to that amount that results in a >10 g / L increase in the subject’s hemoglobin level, compared with the hemoglobin level prior to treatment, provided the blood hemoglobin level does not exceed 130 g / L. In some embodiments, a therapeutically effective dose refers to that amount that results in a >15 g / L increase in the subject’s hemoglobin level, compared with the hemoglobin level prior to treatment, provided the blood hemoglobin level does not exceed 130 g / L. In some embodiments, a therapeutically effective dose refers to that amount that results in a >15 g / L increase in the subject’s hemoglobin level, compared with the hemoglobin level prior to treatment, provided the blood hemoglobin level does not exceed 130 g / L. In some embodiments, a therapeutically effective dose refers to that amount that results in a >20 g / L increase in the subject’s hemoglobin level, compared with the hemoglobin level prior to treatment. In some embodiments, a therapeutically effective doserefers to that amount that results in a >20 g / L increase in the subject’s hemoglobin level, compared with the hemoglobin level prior to treatment, provided the blood hemoglobin level does not exceed 130 g / L.

[0116] In some embodiments, a therapeutically effective dose of roxadustat medicament according to any embodiment described herein is that dose that provides about 50 to 400 mg of roxadustat to the subject. In some embodiments, a therapeutically effective dose according to any embodiment described herein provides about 50 to 250 mg of roxadustat. In some embodiments, a therapeutically effective dose according to any embodiment described herein provides about 100 to 400 mg of roxadustat. In some embodiments, a therapeutically effective dose according to any embodiment described herein provides about 100 to 150 mg of roxadustat. In some embodiments, a therapeutically effective dose according to any embodiment described herein provides an amount of roxadustat selected from the group consisting of 100 mg, 120 mg, and 150 mg. In some embodiments, a therapeutically effective dose according to any embodiment described herein provides about 100 mg of roxadustat. In some embodiments, a therapeutically effective dose according to any embodiment described herein provides about 120 mg of roxadustat. In some embodiments, a therapeutically effective dose according to any embodiment described herein provides about 150 mg of roxadustat.

[0117] In some embodiments, a therapeutically effective dose of roxadustat medicament, according to any embodiment described herein, is based on the weight of the subject. In some embodiments, the subject has a body weight of 40 to <50 kg and the dose of roxadustat is 50-150 mg, particularly about 100 mg. In some embodiments, the subject has a body weight of 50 to 60 kg and the dose of roxadustat is 70-200 mg, particularly about 120 mg. In some embodiments, the subject has a body weight of >60 kg and the dose of roxadustat is 100-250 mg, particularly about 150 mg. In some embodiments, the subject has a body weight of >60 to <80 kg and the dose of roxadustat is 100-200 mg, particularly about 150 mg. In some embodiments, the subject has a body weight of >80 kg and the dose of roxadustat is 150-250 mg, particularly about 200 mg.

[0118] In some embodiments, a therapeutically effective dose of roxadustat medicament, according to any embodiment described herein, is about 1 to 4 mg of roxadustat per kilogram of the subject’s body weight, provided the maximum dose does not exceed 400 mg of roxadustat. In some embodiments, a therapeutically effective dose, according to any embodiment described herein, is about 1 to 3.5 mg of roxadustat per kilogram of the subject’sbody weight, provided the maximum dose does not exceed 400 mg of roxadustat. In some embodiments, a therapeutically effective dose, according to any embodiment described herein, is about 1.5 to 3.5 mg of roxadustat per kilogram of the subject’s body weight, provided the maximum dose does not exceed 400 mg of roxadustat. In some embodiments, a therapeutically effective dose, according to any embodiment described herein, is about 2 to 3.5 mg of roxadustat per kilogram of the subject’s body weight, provided the maximum dose does not exceed 400 mg of roxadustat. In some embodiments, a therapeutically effective dose, according to any embodiment described herein, is about 2 to 2.5 mg of roxadustat per kilogram of the subject’s body weight, particularly about 2.15±0.33 mg / kg.

[0119] In some embodiments, the roxadustat medicament is labeled for administering about 1 to 4 mg of roxadustat per kilogram of the subject’s body weight (1-4 mg / kg) to the subject two to three times a week. In some embodiments, the roxadustat medicament is labeled for administering about 1-3.5 mg / kg to the subject two to three times a week. In some embodiments, the roxadustat medicament is labeled for administering about 1.5-3.5 mg / kg to the subject two to three times a week. In some embodiments, the roxadustat medicament is labeled for administering about 2-3.5 mg / kg to the subject two to three times a week. In some embodiments, the roxadustat medicament is labeled for administering about 2-2.5 mg / kg to the subject two to three times a week.

[0120] In some embodiments, the roxadustat medicament is labeled for administering about 50 to 400 mg of roxadustat to the subject two to three times a week. In some embodiments, the roxadustat medicament is labeled for administering about 50 to 250 mg of roxadustat to the subject two to three times a week. In some embodiments, the roxadustat medicament is labeled for administering about 70 to 200 mg of roxadustat to the subject two to three times a week. In some embodiments, the roxadustat medicament is labeled for administering about 100 to 150 mg of roxadustat, to the subject two to three times a week. In some embodiments, the roxadustat medicament is labeled for administration of a roxadustat dose selected from the group consisting of 100 mg, 120 mg, andl50 mg two to three times per week.

[0121] In some embodiments, the roxadustat medicament is labeled for administering about 1 to 4 mg per kilogram of the subject’s body weight (1-4 mg / kg), to the subject three times a week. In some embodiments, the roxadustat medicament is labeled for administering about 1-3.5 mg / kg to the subject three times a week. In some embodiments, the roxadustat medicament is labeled for administering about 1.5-3.5 mg / kg to the subject three times aweek. In some embodiments, the roxadustat medicament is labeled for administering about 2-3.5 mg / kg to the subject three times a week. In some embodiments, the roxadustat medicament is labeled for administering about 2-2.5 mg / kg to the subject three times a week.

[0122] In some embodiments, the roxadustat medicament is labeled for administering about 50 to 400 mg of roxadustat to the subject three times a week. In some embodiments, the roxadustat medicament is labeled for administering about 50 to 250 mg of roxadustat to the subject three times a week. In some embodiments, the roxadustat medicament is labeled for administering about 70 to 200 mg of roxadustat to the subject three times a week. In some embodiments, the roxadustat medicament is labeled for administering about 100 to 150 mg of roxadustat, to the subject three times a week. In some embodiments, the roxadustat medicament is labeled for administering a dose of roxadustat selected from the group consisting of 100 mg, 120 mg, andl50 mg three times per week.

[0123] In some embodiments, the roxadustat medicament is labeled for administering to a subject having a body weight of 40 to <50 kg about 50 to 150 mg of roxadustat. In particular embodiments, the subject has a body weight of 40 to <50 kg and roxadustat is administered at 50 to 150 mg three times a week. In particular embodiments, the subject has a body weight of 40 to <50 kg and roxadustat is administered at about 100 mg three times a week.

[0124] In some embodiments, the roxadustat medicament is labeled for administering to a subject having a body weight of 50 to 60 kg about 70 to 200 mg of roxadustat. In particular embodiments, the subject has a body weight of 50 to 60 kg and roxadustat is administered at 70 to 200 mg three times a week. In particular embodiments, the subject has a body weight of 50 to 60 kg and roxadustat is administered at about 120 mg three times a week.

[0125] In some embodiments, the roxadustat medicament is labeled for administering to a subject having a body weight >60 kg about 100 to 250 mg of roxadustat. In particular embodiments, the subject has a body weight of >60 kg and roxadustat is administered at 100 to 250 mg three times a week. In particular embodiments, the subject has a body weight of >60 kg and roxadustat is administered at about 150 mg three times a week. In other embodiments, the subject has a body weight of >60 to <80 kg and roxadustat is administered at about 100 to 200 mg three times per week. In other embodiments, the subject has a body weight of >60 to <80 kg and roxadustat is administered at about 150 mg three times a week.

[0126] In some embodiments, the roxadustat medicament is labeled for administering to a subject having a body weight >80 kg about 150 to 250 mg of roxadustat. In particular embodiments, the subject has a body weight of >80 kg and roxadustat is administered at 150 to 250 mg three times a week. In particular embodiments, the subject has a body weight of >80 kg and roxadustat is administered at 200 mg three times a week.

[0127] In some embodiments, the roxadustat medicament is labeled for administering a dose according to any embodiment described herein two to three times per week. In particular embodiments, the roxadustat medicament is labeled for administering a dose according to any embodiment described herein three times per week.

[0128] In some embodiments, the roxadustat medicament is labeled for administering about 50 mg, about 70 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, or about 400 mg of roxadustat to the subject two to three times a week. In some embodiments, the roxadustat medicament is labeled for administering about 50 mg, about 70 mg, about 100 mg, about 120 mg, about 150 mg, about 200 mg, or about 250 mg of roxadustat to the subject three times a week.

[0129] It will be understood by one of skill in the art that the symptoms and outcomes may vary with age, gender, and burden of disease. Based on Hb level, roxadustat doses may be titrated to achieve and maintain a Hb level of 100 to 130 g / L and to minimize the need for blood transfusion. Dose adjustments can be made periodically, for example, once every 4 weeks, by taking into account both the current Hb level and change in Hb level over the period, for example, over the previous 4 weeks.

[0130] In some embodiments, roxadustat is administered at least 2 days apart and no more than 4 days apart. In some embodiments, roxadustat is administered either before or after chemotherapy, but timing should be consistent throughout the course of treatment. In some embodiments, if paclitaxel (e.g., TAXOL or ABRAXANE) is given as part of the chemotherapy regimen, roxadustat dosing is held for 24 hours before or after treatment (time 0 = time of infusion) with paclitaxal.ADDITIONAL EMBODIMENTS

[0131] Embodiments include the following:

[0132] Embodiment 1. Use of roxadustat in the manufacture of a medicament for treating chemotherapy- induced anemia in a subject receiving multi-cycle platinum or nonplatinum myelosuppressive chemotherapy for a non-myeloid malignancy, wherein the subject has a hemoglobin level <100 g / L prior to treatment and the subject's blood hemoglobin level decreased at least 10 g / L after the initiation of chemotherapy.

[0133] Embodiment 2. The use of Embodiment 1, wherein the subject has a serum erythropoietin (Epo) level >200 U / L prior to treatment.

[0134] Embodiment 3. The use of Embodiment 1 or 2, wherein the subject has an estimated glomerular filtration rate (eGFR) >60 mL / min / 1.73m2prior to treatment.

[0135] Embodiment 4. The use of any one of Embodiments 1 to 3, wherein the subject has a transferrin saturation (TSAT) >20% and ferritin >100 ng / mL prior to treatment.

[0136] Embodiment 5. The use of any one of Embodiments 1 to 4, wherein the subject has C-reactive protein (CRP) level < ULN (upper limit of normal) prior to treatment.

[0137] Embodiment 6. The use of any one of Embodiments 1 to 5, wherein the subject is receiving multi-cycle platinum myelosuppressive chemotherapy.

[0138] Embodiment 7. The use of any one of Embodiments 1 to 5, wherein the subject is receiving multi-cycle non-platinum myelosuppressive chemotherapy.

[0139] Embodiment 8. The use of any one of Embodiments 1 to 5, wherein the myelosuppressive chemotherapy is selected from the group consisting of abemaciclib, astragalus mongholicus root, atezolizumab, bevacizumab, calcium folinate, calcium levofolinate, camrelizumab, capecitabine, carboplatin, catequentinib, catequentinib hydrochloride, cetuximab, cisplatin, cyclophosphamide, denosumab, disodium cantharidinate, docetaxel, durvalumab, eleutherococcus senticosus root with rhizome, endostatin, envafolimab, epirubicin hydrochloride, eribulin, eribulin mesilate, etoposide, fluorouracil, fulvestrant, gefitinib, gemcitabine, gemcitabine hydrochloride, gimeracil , inetetamab, irinotecan, irinotecan hydrochloride, liposomal doxorubicin, lobaplatin, mylabris spp., nedaplatin, oteracil potassium, oxaliplatin, paclitaxel, paclitaxel liposome, paclitaxel nanoparticle albumin-bound, panax ginseng root, pegaspargase, pembrolizumab, pemetrexed, pemetrexed disodium, pemetrexed disodium heptahydrate, penpulimab, pyridoxinehydrochloride, pyrotinib maleate, rivoceranib mesylate, sintilimab, tamoxifen, tegafur, tislelizumab, toripalimab, and vinorelbine tartrate.

[0140] Embodiment 9. The use of any one of Embodiments 1 to 8, wherein the non- myeloid malignancy is selected from the group consisting of breast cancer, lung cancer, gastrointestinal cancers, gynecological cancers, pancreatic cancer, and head and neck cancers.

[0141] Embodiment 10. The use of any one of Embodiments 1 to 8, wherein the non- myeloid malignancy is selected from the group consisting of adenocarcinoma gastric, adenocarcinoma of the cervix, adenolymphoma, angiocentric lymphoma, bile duct cancer, bladder transitional cell carcinoma, breast cancer, cervix carcinoma, colon cancer, diffuse large B-cell lymphoma, endometrial cancer, gastric cancer, hepatobiliary cancer, invasive breast carcinoma, invasive ductal breast carcinoma, keratinizing squamous cell carcinoma of nasopharynx, lung adenocarcinoma, lung adenocarcinoma stage IV, lung neoplasm malignant, lung squamous cell carcinoma stage IV, mesothelioma malignant, metastases to abdominal cavity, metastases to adrenals, metastases to bone, metastases to central nervous system, metastases to chest wall, metastases to heart, metastases to liver, metastases to lung, metastases to lymph nodes, metastases to pancreas, metastases to pelvis, metastases to peritoneum, metastases to pharynx, metastases to pleura, metastases to spine, metastases to spleen, nasopharyngeal cancer, neuroendocrine tumor of the lung, esophageal carcinoma, esophageal squamous cell carcinoma, pancreatic carcinoma, ovarian cancer, ovarian cancer stage III, papillary thyroid cancer, peritoneal mesothelioma malignant rectal cancer, sarcomatoid carcinoma of the lung, small cell lung cancer, squamous cell carcinoma of lung, squamous cell carcinoma of the tongue, throat cancer, and uterine cancer.

[0142] Embodiment 11. The use of any one of Embodiments 1 to 10, wherein the subject is receiving chemotherapy for at least 8 weeks after the beginning of treatment.

[0143] Embodiment 12. The use of any one of Embodiments 1 to 11, wherein the subject is >18 years old prior to treatment.

[0144] Embodiment 13. The use of any one of Embodiments 1 to 12, wherein the subject weighs >40 kg prior to treatment.

[0145] Embodiment 14. The use of any one of Embodiments 1 to 13, wherein the subject has Eastern Cooperative Oncology Group performance status (ECOG PS) of 0, 1, or 2 prior to treatment.

[0146] Embodiment 15. The use of any one of Embodiments 1 to 14, wherein the subject has a life expectancy of >6 months at the beginning of treatment.

[0147] Embodiment 16. The use of any one of Embodiments 1 to 15, wherein the roxadustat is crystalline Form A characterized by an X-ray powder diffraction pattern comprising peaks at 8.5, 12.8, 16.2, 21.6, 22.9, and 27.4° 29±0.2° 29.

[0148] Embodiment 17. The use of any one of Embodiments 1 to 16, wherein the roxadustat is a solid having a unimodal particle size distribution of D90 of 21 pm to 29 pm, a D50 of 12 pm to 17 pm, and a DIO of 6 pm to 10 pm.

[0149] Embodiment 18. The use of any one of Embodiments 1 to 17, wherein the medicament is formulated for oral administration.

[0150] Embodiment 19. The use of any one of Embodiments 1 to 18, wherein the medicament further comprises a pharmaceutically acceptable excipient.

[0151] Embodiment 20. The use of any one of Embodiments 1 to 19, wherein the medicament is formulated in a capsule.

[0152] Embodiment 21. The use of Embodiment 20, wherein the capsule comprises 20 mg of roxadustat.

[0153] Embodiment 22. The use of Embodiment 20, wherein the capsule comprises 50 mg of roxadustat.

[0154] Embodiment 23. The use of Embodiment 20, wherein the capsule comprises a capsule fill and a capsule shell, wherein the capsule fill comprises 20 mg of roxadustat and pharmaceutically acceptable excipients comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the capsule shell is a gelatin shell comprising titanium dioxide, iron oxide yellow, and gelatin.

[0155] Embodiment 24. The use of Embodiment 20, wherein the medicament is formulated in a capsule wherein said capsule comprises a capsule fill and a capsule shell; wherein the capsule fill comprises 20 mg of roxadustat, 101.84 mg of lactose monohydrate 310, 9.36 mg of microcrystalline cellulose PH101, 6.48 mg of povidone K30, 5.76 mg of croscarmellose sodium, and 0.56 mg of magnesium stearate; and the capsule shell is a gelatin shell comprising titanium dioxide, iron oxide yellow, and gelatin, wherein the titanium dioxide is 1%, by weight of the capsule shell and the iron oxide yellow is 2% by weight of the capsule shell.

[0156] Embodiment 25. The use of Embodiment 20, wherein the capsule comprises a capsule fill and a capsule shell, wherein the capsule fill comprises 50 mg of roxadustat and pharmaceutically acceptable excipients comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the capsule shell is a gelatin shell comprising Allura red AC, titanium dioxide, iron oxide yellow, and gelatin.

[0157] Embodiment 26. The use of Embodiment 20, wherein the medicament is formulated in a capsule wherein said capsule comprises a capsule fill and a capsule shell; wherein the capsule fill comprises 50 mg of roxadustat, 254.6 mg of lactose monohydrate (310), 23.4 mg of microcrystalline cellulose PH101, 16.20 mg of povidone K30, 14.40 mg of croscarmellose sodium, and 1.4 mg of magnesium stearate; and the capsule shell is a gelatin shell comprising Allura red AC, titanium dioxide, iron oxide yellow, and gelatin, wherein the Allura red AC is 1% by weight of the capsule shell, the titanium dioxide is 1%, by weight of the capsule shell and the iron oxide yellow is 1% by weight of the capsule shell.

[0158] Embodiment 27. The use of any one of Embodiments 1 to 19, wherein the medicament is formulated in a tablet.

[0159] Embodiment 28. The use of Embodiment 27, wherein the tablet comprises 20 mg of roxadustat.

[0160] Embodiment 29. The use of Embodiment 27, wherein the tablet comprises 50 mg of roxadustat.

[0161] Embodiment 30. The use of Embodiment 27, wherein the tablet comprises 70 mg of roxadustat.

[0162] Embodiment 31. The use of Embodiment 27, wherein the tablet comprises 100 mg of roxadustat.

[0163] Embodiment 32. The use of Embodiment 27, wherein the tablet comprises 150 mg of roxadustat.

[0164] Embodiment 33. The use of Embodiment 27, wherein the tablet comprises a tablet core and a coating wherein the tablet core comprises 20 mg of roxadustat and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin.

[0165] Embodiment 34. The use of Embodiment 33, wherein the tablet comprises a tablet core and a coating wherein the tablet core comprises 42.6 mg of lactose monohydrate, 9.12 mg of microcrystalline cellulose, 3.6 mg of povidone K30, 4.0 mg of croscarmellose sodium and 0.68 mg of magnesium stearate and the coating comprises 2.64 mg poly vinyl alcohol, 1.20 mg talc, 0.74 mg macrogol 3350, 0.28 mg titanium dioxide, 0.58 mg Allura Red AC in aluminum lake 38-42%, 0.34 mg Allura Red AC in aluminum lake 15-17% and 0.21 mg lecithin.

[0166] Embodiment 35. The use of Embodiment 27, wherein the tablet comprises a tablet core and a coating wherein the tablet core comprises 50 mg of roxadustat according to any embodiment described herein and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin.

[0167] Embodiment 36. The use of Embodiment 35, wherein the tablet comprises a tablet core and a coating wherein the tablet core comprises 106.5 mg of lactose monohydrate, 22.8 mg of microcrystalline cellulose, 9.0 mg of povidone K30, 10 mg of croscarmellose sodium and 1.7 mg of magnesium stearate and the coating comprises 4.84 mg poly vinyl alcohol, 2.20 mg talc, 1.36 mg macrogol 3350, 0.51 mg titanium dioxide, 1.07 mg Allura Red AC in aluminum lake 38-42%, 0.63 mg Allura Red AC in aluminum lake 15-17% and 0.39 mg lecithin.

[0168] Embodiment 37. The use of Embodiment 27, wherein the tablet comprises a tablet core and a coating wherein the tablet core comprises 70 mg of roxadustat according to any embodiment described herein and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin.

[0169] Embodiment 38. The use of Embodiment 37, wherein the tablet comprises a tablet core and a coating wherein the tablet core comprises 149.1 mg of lactose monohydrate, 31.92 mg of microcrystalline cellulose, 12.6 mg of povidone K30, 14 mg of croscarmellose sodium and 2.38 mg of magnesium stearate and the coating comprises 5.85 mg poly vinyl alcohol, 2.66 mg talc, 1.64 mg macrogol 3350, 0.62 mg titanium dioxide, 1.30 mg Allura RedAC in aluminum lake 38-42%, 0.76 mg Allura Red AC in aluminum lake 15-17% and 0.47 mg lecithin.

[0170] Embodiment 39. The use of Embodiment 27, wherein the tablet comprises a tablet core and a coating wherein the tablet core comprises 100 mg of roxadustat according to any embodiment described herein and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin. In some embodiments, the tablet core comprises lactose monohydrate, microcrystalline cellulose, povidone K30, croscarmellose sodium, and magnesium stearate.

[0171] Embodiment 40. The use of Embodiment 39, wherein the tablet comprises a tablet core and a coating wherein the tablet core comprises 213.0 mg of lactose monohydrate, 45.6 mg of microcrystalline cellulose, 18.0 mg of povidone K30, 20 mg of croscarmellose sodium and 3.4 mg of magnesium stearate and the coating comprises 7.92 mg poly vinyl alcohol, 3.6 mg talc, 2.22 mg macrogol 3350, 0.84 mg titanium dioxide, 1.75 mg Allura Red AC in aluminum lake 38-42%, 1.03 mg Allura Red AC in aluminum lake 15-17% and 0.63 mg lecithin.

[0172] Embodiment 41. The use of Embodiment 27, wherein the tablet comprises a tablet core and a coating wherein the tablet core comprises 150 mg of roxadustat according to any embodiment described herein and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin.

[0173] Embodiment 42. The use of Embodiment 41 , wherein the tablet comprises a tablet core and a coating wherein the tablet core comprises 319.5 mg of lactose monohydrate, 68.4 mg of microcrystalline cellulose, 27.0 mg of povidone K30, 30 mg of croscarmellose sodium and 5.1 mg of magnesium stearate and the coating comprises 10.56 mg poly vinyl alcohol, 4.8 mg talc, 2.96 mg macrogol 3350, 1.12 mg titanium dioxide, 2.34 mg Allura Red AC in aluminum lake 38-42%, 1.38 mg Allura Red AC in aluminum lake 15-17% and 0.84 mg lecithin.

[0174] Embodiment 43. The use of any one of Embodiments 1 to 42, wherein the medicament increases the blood hemoglobin level in the subject following administration compared with the subject's hemoglobin level prior to administration of the medicament.

[0175] Embodiment 44. The use of Embodiment 43, wherein the subject reaches and maintains a hemoglobin level of >100 g / L up to 130 g / L during treatment.

[0176] Embodiment 45. The use of Embodiment 43, wherein the blood hemoglobin level in the subject is increased >10 g / L following administration of the medicament, compared with the subject's hemoglobin level prior to administration of the medicament, provided the blood hemoglobin level does not exceed 130 g / L.

[0177] Embodiment 46. The use of Embodiment 43, wherein the blood hemoglobin level in the subject is increased >15 g / L following administration of the medicament, compared with the subject's hemoglobin level prior to administration of the medicament, provided the blood hemoglobin level does not exceed 130 g / L.

[0178] Embodiment 47. The use of Embodiment 43, wherein the blood hemoglobin level in the subject is increased >20 g / L following administration of the medicament compared with the subject's hemoglobin level prior to administration of the medicament, provided the blood hemoglobin level does not exceed 130 g / L.

[0179] Embodiment 48. The use of any one of Embodiments 1 to 47, wherein the medicament is labeled for administration to the subject based on a dose of roxadustat relative to body weight of the subject.

[0180] Embodiment 49. The use of Embodiment 48, wherein the subject has a body weight of 40 to <50 kg and the dose of roxadustat is 50-150 mg, particularly about 100 mg.

[0181] Embodiment 50. The use of Embodiment 48, wherein the subject has a body weight of 50 to 60 kg and the dose of roxadustat is 70-200 mg, particularly about 120 mg.

[0182] Embodiment 51. The use of Embodiment 48, wherein the subject has a body weight of >60 kg and the dose of roxadustat is 100-250 mg, particularly about 150 mg.

[0183] Embodiment 52. The use of Embodiment 48, wherein the subject has a body weight of >60 to <80 kg and the dose of roxadustat is 100-200 mg, particularly about 150 mg.

[0184] Embodiment 53. The use of Embodiment 48, wherein the subject has a body weight of >80 kg and the dose of roxadustat is 150-250 mg, particularly about 200 mg.

[0185] Embodiment 54. The use of Embodiment 48, wherein the dose is about 1 to 4 milligrams of roxadustat per kilogram of the subject's body weight.

[0186] Embodiment 55. The use of Embodiment 48, wherein the dose is about 1 to 3.5 milligrams of roxadustat per kilogram of the subject's body weight.

[0187] Embodiment 56. The use of Embodiment 48, wherein the dose is about 1.5 to 3.5 milligrams of roxadustat per kilogram of the subject's body weight.

[0188] Embodiment 57. The use of Embodiment 48, wherein the dose is about 2.0 to 3.5 milligrams of roxadustat per kilogram of the subject's body weight.

[0189] Embodiment 58. The use of Embodiment 48, wherein the dose is about 2.0 to 2.5 milligrams of roxadustat per kilogram of the subject's body weight, particularly about 2.15±0.33 mg / kg.

[0190] Embodiment 59. The use of any one of Embodiments 1 to 58, wherein the medicament is labeled to administer a dose of roxadustat three times a week.

[0191] Embodiment 60. The use of any one of Embodiments 1 to 42, wherein the medicament is labeled for treating anemia in a subject receiving multi-cycle platinum or nonplatinum myelosuppressive chemotherapy for a non-myeloid malignancy, wherein the subject has a blood hemoglobin level <100 g / L prior to treatment, and comprises orally administering to the subject 100 mg to 150 mg of roxadustat three times a week, wherein the subject achieves a hemoglobin level of >110 g / L to 130 g / L during treatment.

[0192] Embodiment 61. The use of any one of Embodiments 1 to 42, wherein the medicament is labeled for treating anemia in a subject receiving multi-cycle platinum or nonplatinum myelosuppressive chemotherapy for a non-myeloid malignancy, wherein the subject has a blood hemoglobin level <100 g / L prior to treatment, and comprises orally administering to the subject 50 mg to 400 mg of roxadustat three times a week, wherein the blood hemoglobin level in the subject is increased following administration of the roxadustat, compared with the subject's hemoglobin level prior to administration of the roxadustat provided the blood hemoglobin level does not exceed 130 g / L; provided the roxadustat is administered at least 2 days apart and no more than 4 days apart; and provided that if the subject is receiving paclitaxel as part of the myelosuppressive chemotherapy, roxadustat dosing is held for 24 hours before or after the subject receives the paclitaxel.

[0193] Embodiment 62. The use of any one of Embodiments 1 to 42, wherein the medicament is labeled for treating anemia in a subject receiving multi-cycle platinum or nonplatinum myelosuppressive chemotherapy for a non-myeloid malignancy, wherein the subject has a blood hemoglobin level <100 g / L prior to treatment, and comprises orally administering to the subject 2.0 to 3.5 milligrams of roxadustat per kilogram of the subject's body weight three times a week, wherein the blood hemoglobin level in the subject is increased following administration of the roxadustat, compared with the subject's hemoglobin level prior to administration of the roxadustat, provided the blood hemoglobin level does not exceed 130 g / L; provided the roxadustat is administered at least 2 days apart and no more than 4 days apart; provided the dose does not exceed 400 mg; and provided that if the subject is receiving paclitaxel as part of the myelosuppressive chemotherapy, roxadustat dosing is held for 24 hours before or after the subject receives the paclitaxel.

[0194] Embodiment 63. The use of any one of Embodiments 1 to 62, wherein the medicament is further labeled to optionally increase or decrease the dose of roxadustat until the subject achieves and maintains a blood hemoglobin level of 100 to 120 g / L, providing the dose does not exceed 400 mg.

[0195] Embodiment 64. The use of Embodiment 63, wherein the increasing or decreasing the dose of roxadustat results in a dose of 50 mg, 70 mg, 100 mg, 120 mg, 150 mg, 200 mg, 250 mg, 300 mg, or 400 mg.

[0196] Embodiment Bl. A method of treating chemotherapy-induced anemia in a subject receiving multi-cycle platinum or non-platinum myelosuppressive chemotherapy for a non- myeloid malignancy, wherein the subject has a hemoglobin level <100 g / L prior to treatment and the subject's blood hemoglobin level decreased at least 10 g / L after the initiation of chemotherapy, comprising administering roxadustat to the subject.

[0197] Embodiment B2. The use of Embodiment B 1 , wherein the subject has a serum erythropoietin (Epo) level >200 U / L prior to treatment.

[0198] Embodiment B3. The method of Embodiment Bl or B2, wherein the subject has an estimated glomerular filtration rate (eGFR) >60 mL / min / 1.73m2prior to treatment.

[0199] Embodiment B4. The method of any one of Embodiments Bl to B3, wherein the subject has a transferrin saturation (TSAT) >20% and ferritin >100 ng / mL prior to treatment.

[0200] Embodiment B5. The method of any one of Embodiments Bl to B4, wherein the subject has C-reactive protein (CRP) level < ULN (upper limit of normal) prior to treatment.

[0201] Embodiment B6. The method of any one of Embodiments Bl to B5, wherein the subject is receiving multi-cycle platinum myelosuppressive chemotherapy.

[0202] Embodiment B7. The method of any one of Embodiments Bl to B5, wherein the subject is receiving multi-cycle non-platinum myelosuppressive chemotherapy.

[0203] Embodiment B8. The method of any of one of Embodiments Bl to B5, wherein the myelosuppressive chemotherapy is selected from the group consisting of abemaciclib, astragalus mongholicus root, atezolizumab, bevacizumab, calcium folinate, calcium levofolinate, camrelizumab, capecitabine, carboplatin, catequentinib, catequentinib hydrochloride, cetuximab, cisplatin, cyclophosphamide, denosumab, disodium cantharidinate, docetaxel, durvalumab, eleutherococcus senticosus root with rhizome, endostatin, envafolimab, epirubicin hydrochloride, eribulin, eribulin mesilate, etoposide, fluorouracil, fulvestrant, gefitinib, gemcitabine, gemcitabine hydrochloride, gimeracil , inetetamab, irinotecan, irinotecan hydrochloride, liposomal doxorubicin, lobaplatin, mylabris spp., nedaplatin, oteracil potassium, oxaliplatin, paclitaxel, paclitaxel liposome, paclitaxel nanoparticle albumin-bound, panax ginseng root, pegaspargase, pembrolizumab, pemetrexed, pemetrexed disodium, pemetrexed disodium heptahydrate, penpulimab, pyridoxine hydrochloride, pyrotinib maleate, rivoceranib mesylate, sintilimab, tamoxifen, tegafur, tislelizumab, toripalimab, and vinorelbine tartrate.

[0204] Embodiment B9. The method of any one of Embodiments Bl to B8, wherein the non-myeloid malignancy is selected from the group consisting of breast cancer, lung cancer, gastrointestinal cancers, gynecological cancers, pancreatic cancer, and head and neck cancers.

[0205] Embodiment B10. The method of any one of Embodiments Bl to B8, wherein the non-myeloid malignancy is selected from the group consisting of adenocarcinoma gastric, adenocarcinoma of the cervix, adenolymphoma, angiocentric lymphoma, bile duct cancer, bladder transitional cell carcinoma, breast cancer, cervix carcinoma, colon cancer, diffuse large B-cell lymphoma, endometrial cancer, gastric cancer, hepatobiliary cancer, invasive breast carcinoma, invasive ductal breast carcinoma, keratinizing squamous cell carcinoma of nasopharynx, lung adenocarcinoma, lung adenocarcinoma stage IV, lung neoplasm malignant, lung squamous cell carcinoma stage IV, mesothelioma malignant, metastases to abdominal cavity, metastases to adrenals, metastases to bone, metastases to central nervous system, metastases to chest wall, metastases to heart, metastases to liver, metastases to lung, metastases to lymph nodes, metastases to pancreas, metastases to pelvis, metastases toperitoneum, metastases to pharynx, metastases to pleura, metastases to spine, metastases to spleen, nasopharyngeal cancer, neuroendocrine tumor of the lung, esophageal carcinoma, esophageal squamous cell carcinoma, pancreatic carcinoma, ovarian cancer, ovarian cancer stage III, papillary thyroid cancer, peritoneal mesothelioma malignant rectal cancer, sarcomatoid carcinoma of the lung, small cell lung cancer, squamous cell carcinoma of lung, squamous cell carcinoma of the tongue, throat cancer, and uterine cancer.

[0206] Embodiment Bl 1. The method of any one of Embodiments Bl to BIO, wherein the subject is receiving chemotherapy for at least 8 weeks after the beginning of treatment.

[0207] Embodiment Bl 2. The method of any one of Embodiments Bl to Bl 1, wherein the subject is >18 years old prior to treatment.

[0208] Embodiment B13. The method of any one of Embodiments Bl to B12, wherein the subject weighs >40 kg prior to treatment.

[0209] Embodiment B14. The method of any one of Embodiments Bl to B13, wherein the subject has Eastern Cooperative Oncology Group performance status (ECOG PS) of 0, 1, or 2 prior to treatment.

[0210] Embodiment B15. The method of any one of Embodiments Bl to B14, wherein the subject has a life expectancy of >6 months at the beginning of treatment.

[0211] Embodiment Bl 6. The method of any one of Embodiments Bl to Bl 5, wherein the roxadustat is crystalline Form A characterized by an X-ray powder diffraction pattern comprising peaks at 8.5, 12.8, 16.2, 21.6, 22.9, and 27.4° 29±0.2° 29.

[0212] Embodiment Bl 7. The method of any one of Embodiments Bl to Bl 6, wherein the roxadustat is a solid having a unimodal particle size distribution of D90 of 21 pm to 29 pm, a D50 of 12 pm to 17 pm, and a D10 of 6 pm to 10 pm.

[0213] Embodiment Bl 8. The method of any one of Embodiments Bl to Bl 7, wherein the roxadustat is formulated for oral administration.

[0214] Embodiment Bl 9. The method of any one of Embodiments Bl to Bl 8, wherein the roxadustat is administered as a pharmaceutical composition comprising roxadustat and a pharmaceutically acceptable excipient.

[0215] Embodiment B20. The method of Embodiment Bl 9, wherein the pharmaceutical composition is a capsule.

[0216] Embodiment B21. The method of Embodiment B20, wherein the capsule comprises 20 mg of roxadustat.

[0217] Embodiment B22. The method of Embodiment B20, wherein the capsule comprises 50 mg of roxadustat.

[0218] Embodiment B23. The method of Embodiment B20, wherein the capsule comprises a capsule fill and a capsule shell, wherein the capsule fill comprises 20 mg of roxadustat and pharmaceutically acceptable excipients comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the capsule shell is a gelatin shell comprising titanium dioxide, iron oxide yellow, and gelatin.

[0219] Embodiment B24. The method of Embodiment B20, wherein the capsule comprises a capsule fill and a capsule shell; wherein the capsule fill comprises 20 mg of roxadustat, 101.84 mg of lactose monohydrate 310, 9.36 mg of microcrystalline cellulose PH101, 6.48 mg of povidone K30, 5.76 mg of croscarmellose sodium, and 0.56 mg of magnesium stearate; and the capsule shell is a gelatin shell comprising titanium dioxide, iron oxide yellow, and gelatin, wherein the titanium dioxide is 1%, by weight of the capsule shell and the iron oxide yellow is 2% by weight of the capsule shell.

[0220] Embodiment B25. The method of Embodiment B20, wherein the capsule comprises a capsule fill and a capsule shell, wherein the capsule fill comprises 50 mg of roxadustat and pharmaceutically acceptable excipients comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the capsule shell is a gelatin shell comprising Allura red AC, titanium dioxide, iron oxide yellow, and gelatin.

[0221] Embodiment B26. The method of Embodiment B20, wherein the capsule comprises a capsule fill and a capsule shell; wherein the capsule fill comprises 50 mg of roxadustat, 254.6 mg of lactose monohydrate (310), 23.4 mg of microcrystalline cellulose PH101, 16.20 mg of povidone K30, 14.40 mg of croscarmellose sodium, and 1.4 mg of magnesium stearate; and the capsule shell is a gelatin shell comprising Allura red AC, titanium dioxide, iron oxide yellow, and gelatin, wherein the Allura red AC is 1 % by weight of the capsule shell, the titanium dioxide is 1%, by weight of the capsule shell and the iron oxide yellow is 1% by weight of the capsule shell.

[0222] Embodiment B27. The method of Embodiment Bl 9, wherein the pharmaceutical composition is a tablet.

[0223] Embodiment B28. The method of Embodiment B27, wherein the tablet comprises 20 mg of roxadustat.

[0224] Embodiment B29. The method of Embodiment B27, wherein the tablet comprises 50 mg of roxadustat.

[0225] Embodiment B30. The method of Embodiment B27, wherein the tablet comprises 70 mg of roxadustat.

[0226] Embodiment B31. The method of Embodiment B27, wherein the tablet comprises 100 mg of roxadustat.

[0227] Embodiment B32. The method of Embodiment B27, wherein the tablet comprises 150 mg of roxadustat.

[0228] Embodiment B33. The method of Embodiment B27, wherein the tablet comprises a tablet core and a coating wherein the tablet core comprises 20 mg of roxadustat and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin.

[0229] Embodiment B34. The method of Embodiment B33, wherein the tablet comprises a tablet core and a coating wherein the tablet core comprises 42.6 mg of lactose monohydrate, 9.12 mg of microcrystalline cellulose, 3.6 mg of povidone K30, 4.0 mg of croscarmellose sodium and 0.68 mg of magnesium stearate and the coating comprises 2.64 mg poly vinyl alcohol, 1.20 mg talc, 0.74 mg macrogol 3350, 0.28 mg titanium dioxide, 0.58 mg Allura Red AC in aluminum lake 38-42%, 0.34 mg Allura Red AC in aluminum lake 15-17% and 0.21 mg lecithin.

[0230] Embodiment B35. The method of Embodiment B27, wherein the tablet comprises a tablet core and a coating wherein the tablet core comprises 50 mg of roxadustat according to any embodiment described herein and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin.

[0231] Embodiment B36. The method of Embodiment B35, wherein the tablet comprises a tablet core and a coating wherein the tablet core comprises 106.5 mg of lactose monohydrate, 22.8 mg of microcrystalline cellulose, 9.0 mg of povidone K30, 10 mg of croscarmellose sodium and 1.7 mg of magnesium stearate and the coating comprises 4.84 mg poly vinyl alcohol, 2.20 mg talc, 1.36 mg macrogol 3350, 0.51 mg titanium dioxide, 1.07 mg Allura Red AC in aluminum lake 38-42%, 0.63 mg Allura Red AC in aluminum lake 15-17% and 0.39 mg lecithin.

[0232] Embodiment B37. The method of Embodiment B27, wherein the tablet comprises a tablet core and a coating wherein the tablet core comprises 70 mg of roxadustat according to any embodiment described herein and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin.

[0233] Embodiment B38. The method of Embodiment B37, wherein the tablet comprises a tablet core and a coating wherein the tablet core comprises 149.1 mg of lactose monohydrate, 31.92 mg of microcrystalline cellulose, 12.6 mg of povidone K30, 14 mg of croscarmellose sodium and 2.38 mg of magnesium stearate and the coating comprises 5.85 mg poly vinyl alcohol, 2.66 mg talc, 1.64 mg macrogol 3350, 0.62 mg titanium dioxide, 1.30 mg Allura Red AC in aluminum lake 38-42%, 0.76 mg Allura Red AC in aluminum lake 15- 17% and 0.47 mg lecithin.

[0234] Embodiment B39. The method of Embodiment B27, wherein the tablet comprises a tablet core and a coating wherein the tablet core comprises 100 mg of roxadustat according to any embodiment described herein and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin. In some embodiments, the tablet core comprises lactose monohydrate, microcrystalline cellulose, povidone K30, croscarmellose sodium, and magnesium stearate.

[0235] Embodiment B40. The method of Embodiment B39, wherein the tablet comprises a tablet core and a coating wherein the tablet core comprises 213.0 mg of lactose monohydrate, 45.6 mg of microcrystalline cellulose, 18.0 mg of povidone K30, 20 mg of croscarmellose sodium and 3.4 mg of magnesium stearate and the coating comprises 7.92 mgpoly vinyl alcohol, 3.6 mg talc, 2.22 mg macrogol 3350, 0.84 mg titanium dioxide, 1.75 mg Allura Red AC in aluminum lake 38-42%, 1.03 mg Allura Red AC in aluminum lake 15-17% and 0.63 mg lecithin.

[0236] Embodiment B41. The method of Embodiment B27, wherein the tablet comprises a tablet core and a coating wherein the tablet core comprises 150 mg of roxadustat according to any embodiment described herein and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin.

[0237] Embodiment B42. The method of Embodiment B41, wherein the tablet comprises a tablet core and a coating wherein the tablet core comprises 319.5 mg of lactose monohydrate, 68.4 mg of microcrystalline cellulose, 27.0 mg of povidone K30, 30 mg of croscarmellose sodium and 5.1 mg of magnesium stearate and the coating comprises 10.56 mg poly vinyl alcohol, 4.8 mg talc, 2.96 mg macrogol 3350, 1.12 mg titanium dioxide, 2.34 mg Allura Red AC in aluminum lake 38-42%, 1.38 mg Allura Red AC in aluminum lake 15- 17% and 0.84 mg lecithin.

[0238] Embodiment B43. The method of any one of Embodiments Bl to B42, wherein the blood hemoglobin level in the subject is increased following administration of the roxadustat, compared with the subject's hemoglobin level prior to administration of the roxadustat.

[0239] Embodiment B44. The method of Embodiment B43, wherein the subject reaches and maintains a hemoglobin level of >100 g / L up to 130 g / L during treatment.

[0240] Embodiment B45. The method of Embodiment B43, wherein the blood hemoglobin level in the subject is increased >10 g / L following administration of the roxadustat, compared with the subject's hemoglobin level prior to administration of the roxadustat, provided the blood hemoglobin level does not exceed 130 g / L.

[0241] Embodiment B46. The method of Embodiment B43, wherein the blood hemoglobin level in the subject is increased >15 g / L following administration of the roxadustat, compared with the subject's hemoglobin level prior to administration of the roxadustat, provided the blood hemoglobin level does not exceed 130 g / L.

[0242] Embodiment B47. The method of Embodiment B43, wherein the blood hemoglobin level in the subject is increased >20 g / L following administration of theroxadustat, compared with the subject's hemoglobin level prior to administration of the roxadustat, provided the blood hemoglobin level does not exceed 130 g / L.

[0243] Embodiment B48. The method of any one of Embodiments Bl to B47, wherein the roxadustat is administered to the subject based on a dose of roxadustat relative to body weight of the subject.

[0244] Embodiment B49. The method of Embodiment B48, wherein the subject has a body weight of 40 to <50 kg and the dose of roxadustat is 50-150 mg.

[0245] Embodiment B50. The method of Embodiment B49, wherein the dose of roxadustat is about 100 mg.

[0246] Embodiment B51. The method of Embodiment B48, wherein the subject has a body weight of 50 to 60 kg and the dose of roxadustat is 70-200 mg.

[0247] Embodiment B52. The method of Embodiment B51, wherein the dose of roxadustat is about 120 mg.

[0248] Embodiment B53. The method of Embodiment B48, wherein the subject has a body weight of >60 kg and the dose of roxadustat is 100-250 mg.

[0249] Embodiment B54. The method of Embodiment B53, wherein the dose of roxadustat is about 150 mg.

[0250] Embodiment B55. The method of Embodiment B48, wherein the subject has a body weight of >60 to <80 kg and the dose of roxadustat is 100-200 mg.

[0251] Embodiment B56. The method of Embodiment B55, wherein the dose of roxadustat is about 150 mg.

[0252] Embodiment B57. The method of Embodiment B48, wherein the subject has a body weight of >80 kg and the dose of roxadustat is 150-250 mg.

[0253] Embodiment B58. The method of Embodiment B57, wherein the dose of roxadustat is about 200 mg.

[0254] Embodiment B59. The method of Embodiment B48, wherein the dose is about 1 to 4 milligrams of roxadustat per kilogram of the subject's body weight.

[0255] Embodiment B60. The method of Embodiment B48, wherein the dose is about 1 to 3.5 milligrams of roxadustat per kilogram of the subject's body weight.

[0256] Embodiment B61. The method of Embodiment B48, wherein the dose is about E5 to 3.5 milligrams of roxadustat per kilogram of the subject's body weight.

[0257] Embodiment B62. The method of Embodiment B48, wherein the dose is about 2.0 to 3.5 milligrams of roxadustat per kilogram of the subject's body weight.

[0258] Embodiment B63. The method of Embodiment B48, wherein the dose is about 2.0 to 2.5 milligrams of roxadustat per kilogram of the subject's body weight.

[0259] Embodiment B64. The method of Embodiment B48, wherein the dose is about 2.15±0.33 mg / kg of the subject's body weight.

[0260] Embodiment B65. The method of any one of Embodiments Bl to B64, wherein the roxadustat is administered three times a week.

[0261] Embodiment B66. The method of any one of Embodiments Bl to B42, wherein the method comprises orally administering to the subject 100 mg to 150 mg of roxadustat three times a week, wherein the subject achieves a hemoglobin level of >110 g / L to 130 g / L during treatment.

[0262] Embodiment B67. The method of any one of Embodiments Bl to B42, wherein the method comprises orally administering to the subject 50 mg to 400 mg of roxadustat three times a week, wherein the blood hemoglobin level in the subject is increased following administration of the roxadustat, compared with the subject's hemoglobin level prior to administration of the roxadustat provided the blood hemoglobin level does not exceed 130 g / L; provided the roxadustat is administered at least 2 days apart and no more than 4 days apart; and provided that if the subject is receiving paclitaxel as part of the myelosuppressive chemotherapy, roxadustat dosing is held for 24 hours before or after the subject receives the paclitaxel.

[0263] Embodiment B68. The method of any one of Embodiments Bl to B42, wherein the method comprises orally administering to the subject 2.0 to 3.5 milligrams of roxadustat per kilogram of the subject's body weight three times a week, wherein the blood hemoglobin level in the subject is increased following administration of the roxadustat, compared with the subject's hemoglobin level prior to administration of the roxadustat, provided the blood hemoglobin level does not exceed 130 g / L; provided the roxadustat is administered at least 2 days apart and no more than 4 days apart; provided the dose does not exceed 400 mg; and provided that if the subject is receiving paclitaxel as part of the myelosuppressivechemotherapy, roxadustat dosing is held for 24 hours before or after the subject receives the paclitaxel.

[0264] Embodiment B69. The method of any one of Embodiments Bl to B68, wherein the dose of roxadustat is optionally increased or decreased until the subject achieves and maintains a blood hemoglobin level of 100 to 120 g / L, providing the dose does not exceed 400 mg.

[0265] Embodiment B70. The method of Embodiment B69, wherein the increasing or decreasing the dose of roxadustat results in a dose of 50 mg, 70 mg, 100 mg, 120 mg, 150 mg, 200 mg, 250 mg, 300 mg, or 400 mg.EXAMPLES

[0266] Example 1: A Randomized, Open-label, Active-controlled, Multicenter Phase 3 Study to Investigate the Efficacy and Safety of Roxadustat for Treatment of Anemia in Subjects Receiving Chemotherapy Treatment for Non-Myeloid Malignancies

[0267] Study Design

[0268] The study consisted of a Screening Period of maximum 4 weeks, followed by a 12- week Treatment Period and a subsequent 4-week Follow-up Period (FIG 1.).

[0269] Screening Period (up to 4 weeks): all screening procedures were completed prior to Study Day 1 to determine eligibility for participation in this study.

[0270] Treatment Period (12 weeks): subjects determined to be eligible for participation were randomized to roxadustat and SEPO® (recombinant human erythropoietin-a [rHuEPO- a]) at a 1: 1 ratio and stratified by screening Hb level (<90 g / L or >90 g / L), tumor type (lung, breast, or others), and chemotherapy regimen (i.e., platinum vs. non-platinum) on Study Day 1. The subjects underwent 12 weeks of study treatment. Study visits were scheduled every 2 weeks to regularly evaluate subjects’ clinical status and safety.

[0271] Follow-up Period (4 weeks after the early termination [ET] / end of treatment [EOT] visit): all subjects who completed 12 weeks of treatment with roxadustat or SEPO® underwent a 4-week follow-up period. Subjects who discontinued treatment early were encouraged to complete the EOT visit and 4-week follow-up visit and continue to complete study visits until the completion of week 17 visit.

[0272] Enrolled subjects were receiving best supportive care. If a subject’s condition changed and the subject required transfusion, the subject could receive transfusion while participating in the study.

[0273] Additionally, Independent Data Monitoring Committee was established, and periodical review of efficacy and safety data was performed during the study. Special attention was paid to subjects who experienced thromboembolic events.

[0274] Target Subjects Population and Sample Size

[0275] Subjects aged more than 18 years with diagnosis of non-myeloid malignancy, by histological or cytological confirmation, and weighed more than 40 kg, with Eastern Cooperative Oncology Group performance status (ECOG PS) of 0, 1, or 2, estimated life expectancy >6 months at enrollment, Ferritin >50 ng / mL and transferrin saturation (TSAT) >10% were included in the study. Subjects must also have anemia related to myelosuppressive chemotherapy (defined as Hb <100 g / L at screening with documented subject’s Hb level decrease no less than 10 g / L after the initiation of chemotherapy as judged by the investigator) and planned to receive concurrent treatment of cancer (myelosuppressive chemotherapy) for at least 8 additional weeks after enrollment (Study Day 1).

[0276] The study was conducted across 44 centers and enrolled 159 subjects (82 subjects to roxadustat and 77 subjects to SEPO) and 155 subjects were treated (81 subjects in the roxadustat group and 74 subjects in the SEPO group). Of the randomized subjects, 102 (64.2%) subjects completed study treatment in accordance with the protocol (60 subjects in the roxadustat group and 42 subjects in the SEPO group). All 155 treated subjects were included in the Safety Analysis Set, 144 (90.6%) subjects in the Full Analysis Set (FAS), and 140 (88.1%) subjects in the Per Protocol Set (PPS).

[0277] The FAS was defined as all randomized subjects who received at least one dose of study drug and had at least one non-missing postbaseline Hb value. The FAS analyses were performed based on the treatment randomized even if the subject did not receive the correct treatment. The PPS included all FAS subjects without major protocol deviations that influenced the evaluation of the primary endpoint. The Safety Analysis Set (SAF) was defined as all subjects who took at least one dose of study drug. The SAF population analyses were performed by the treatment received.

[0278] Key demographics and baseline characteristics of the Full Analysis Set (FAS) are shown in Table 2. Baseline Stratification and Tumor Stage of the FAS are shown in Table 3.

[0279] Table 2 FAS Demographics

[0280] Table 3 FAS Baseline Stratification and Tumor Stage

[0281] Treatment of Subjects

[0282] Roxadustat'.

[0283] Roxadustat was administered orally 3 times per week (TIW) to achieve Hb levels of 100-120 g / L. The starting dose for roxadustat was based on the subject’s weight group (Table 4). The maximum dose for individual subjects could not exceed 3.5 mg / kg or 400 mg TIW whichever was lower. Dose modification / adjustments evaluation occurred every 4 weeks, and dose was titrated to Hb level and rate of Hb change. However, if a subject received RBC transfusion, the timing of the next dose adjustment was to be discussed with the medical monitor.

[0284] Table 4 Roxadustat Starting Dose

[0285] SEPO®:

[0286] SEPO® was injected subcutaneously TIW and avoided hematocrit (HCT) >36% to achieve Hb levels of 100-120 g / L. The starting dose for SEPO® was 150 fU / kg. Dose modifications / adjustments evaluation could occur at any time during the study based on the subject’s local Hb and HCT values.

[0287] Chemotherapy.

[0288] The dose, route, and schedule for administration of any chemotherapeutic agent were decided and administered per treating physicians according to standard treatment algorithms.

[0289] Roxadustat or SEPO® could be given either before or after chemotherapy, but timing should be consistent throughout the course of the study.

[0290] Treatment compliance:

[0291] Roxadustat or SEPO® was dispensed by qualified personnel at the investigational sites; dosing history and study treatment reconciliation were documented in the corresponding case report form (CRF).

[0292] Study Objectives and Endpoints

[0293] Roxadustat demonstrated non-inferiority compared to recombinant erythropoietin alfa (SEPO®) on the primary endpoint which was defined as change in hemoglobin (Hb) level from baseline to the level averaged during weeks 9-13 (FIGs 2A-2B). Based on mixed model repeated measures (MMRM) analysis for the primary endpoint, the lower bound of the 1-sided 97.5% confidence interval (CI) for the treatment difference (-3.39g / L) of mean change from baseline in Hb between roxadustat arm and SEPO arm was > -6.6 g / L (predefined non-inferiority margin) in the per protocol set (PPS). The results of the FAS analysis also support this conclusion with the lower bound of the 1 -sided 97.5% CI for the treatment difference being (-2.53g / L) g / L.

[0294] As shown in Table 5, the change in Hb level from baseline to the level averaged during weeks 9-13 in different tumor types are generally consistent with the primary endpoint.

[0295] Table 5 Hb Increase by Tumor Type

[0296] As shown in Table 6, roxadustat also demonstrated non-inferiority compared toSEPO® with respect to percentage of subjects with >10 g / L increase in hemoglobin from baseline through week 13. The lower bound of the 1-sided 97.5% CI for the difference -6.4% between roxadustat arm and SEPO arm was > -15% (predefined non-inferiority margin) in PPS, indicating the proportion of subjects who achieved a >10 g / L increase from baseline in Hb during treatment period was comparable between roxadustat arm and SEPO arm.

[0297] Table 6 Percent Subjects with >10 g / L Increase in Hb

[0298] As shown in Table 7, the proportion of subjects who achieved a > 10 g / L increase in hemoglobin from baseline through week 13 in tumor type and chemotherapy regimen subgroups (per protocol set; PPS) is also generally consistent to the findings in the overall population.

[0299] Table 7 Subgroup Analysis of Percent Subjects with >10 g / L Increase in Hb

[0300] FIG. 3 shows a Forest plot of primary efficacy results in subgroups. The LSM difference of roxadustat group over SEPO group with 95% two-sided confidence interval is shown by comparing with -6.6 (predefined non-inferiority margin). As shown in FIG. 3, the various subgroup analyses were also generally consistent with the primary analysis. Notably, roxadustat generally appeared to perform better in subjects having an initial serum erythropoietin (Epo) level >200 U / L. These subjects demonstrate functioning kidneys with respect to erythropoietin response, suggesting their anemia is due to the myelosuppressive chemotherapeutic agent rather than Epo deficiency.

[0301] Roxadustat was originally indicated for kidney anemia which is a type of chronic inflammatory anemia, which influences the erythropoiesis processes via inhibition of EPO production, while roxadustat was found to be able to transiently increased endogenous EPO levels within or near physiological range in patients. On the contrary, FIG. 3 indicates that in the subjects having an initial serum erythropoietin (Epo) level >200 U / L, the lower end of LSM difference is -2.30, higher than -6.6 (predefined non-inferiority margin), while the subjects having an initial serum erythropoietin (Epo) level < 200 U / L do not show the same tendency. This result is quite surprising, indicating that roxadustat seems to provide more benefits in the CIA patients with a higher Epo level. Similar tendency can also be found in subjects having a TSAT > 20% and ferritin > 100 ng / mL.

[0302] As shown in Table 8, non-inferiority between the roxadustat and the SEPO arms for the three patient-reported outcome (PRO) endpoints were established, the lower bounds of the 1 -sided CI for the difference were greater than predefined non-inferiority (NI) margins.

[0303] Table 8 Improvement in PRO (per protocol set, PPS)*CFB: change from baseline; bold indicates inferiority or non-inferiority of relevance

[0304] As shown in Table 9, the roxadustat arm had a numerically higher proportion of subjects who achieved Hb > 110 g / L, Hb > 110 g / L or > 15 g / L, or Hb > 100 g / L increase than the SEPO arm.

[0305] Table 9 Proportion of Subjects Who Achieved >100 / 110 g / L or > llOg / L or >15 g / L Hb Increase

[0306] As shown in Table 10, the proportion of subjects in the FAS dataset who achieved an increase in Hb > 10, > 15, or > 20 g / L was numerically higher for patients in the roxadustat arm. Also, a shorter period of time was needed to achieve > 15 or > 20 g / L Hb increase (42 vs. 52 days for > 15 g / L Hb increase and 57 vs. 77 days for > 20 g / L Hb increase, respectively), which may have clinical significance.

[0307] Table 10 Proportion of Subjects Who Achieved > 10 / 15 / 20 g / L Hb Increase and Time to Increase (FAS)

[0308] Percent non-responders, defined as any subject that required RBC transfusion or with any Hb < 60 g / L from week 5 through week 13 is shown in Table 11. The upper bound of the 1 -sided CI for the difference 7.4%, of % non-responders to treatment between roxadustat arm and SEPO arm was < 12.5% (predefined NI margin), indicating the comparability between roxadustat arm and SEPO arm. PPS is the primary analysis for noninferiority testing of primary and all secondary endpoints.

[0309] Table 11 Percent Non-Responders in PPS and FAS

[0310] The proportion of subjects (PPS) that required RBC transfusion or had Hb < 60 g / L from week 5 through week 13 in tumor type and chemotherapy regimen subgroups is shown in Table 12. The subgroup analysis for key secondary endpoints is generally consistent with the findings in the overall population.

[0311] Table 12 Percent Non-Responders in PPS Subgroups

[0312] The proportion of subjects requiring RBC transfusion or ESA rescue is shown inTable 13. A numerically lower proportion of subjects in the roxadustat arm received RBC transfusion. The incidence of RBC transfusion (time per week) was lower (Rate Ratio 0.225, 95% CI 0.084, 0.603) in the roxadustat group, and the Hazard Ratio for RBC transfusion between the 2 arms was 0.622 (95% CI 0.208, 1.861).

[0313] Table 13 Proportion of Subjects Requiring RBC Transfusion or ESA Rescue

[0314] Response in subjects based on baseline erythropoietin levels are shown in Table 14. Subjects treated with roxadustat responded similarly regardless of baseline erythropoietin level, whereas SEPO was less efficacious in subjects having baseline erythropoietin levels > 200 U / L.

[0315] Table 14 Changes from Baseline in Erythropoietin Test Results (Full Analysis Set)

[0316] Summary of Safety

[0317] The incidence of any treatment emergent adverse events (TEAEs) was similar between treatment arms, and the exposure adjusted incidence was lower in the roxadustat group. There was a lower proportion of patients with drug related TEAE and TEAE leading to drug discontinuation in the roxadustat group compared with the SEPO group. The proportion of patients with TEAEs with Common Terminology Criteria for Adverse Events (CTCAE) > Grade 3 was slightly numerically higher in the roxadustat group compared with the SEPO group.

[0318] The proportion of patients with treatment emergent serious adverse events (TESAEs) was numerically higher in the roxadustat group compared with the SEPO group (29.6% vs. 21.6%). Most of the SAEs were reported sporadically. For TESAEs reported in >2 subjects, preferred terms (PTs) “Myelosuppression” and “Neutrophil count decreased” were more frequently reported in the roxadustat group than in the SEPO group. These are common conditions in patients undergoing chemotherapy for cancer.

[0319] For common TEAEs (reported >5% in any treatment group), AST increased, ALT increased, blood LDH increased, back pain, cancer pain, and dizziness were reported 2- fold higher in the roxadustat group compared to the SEPO group. Vertigo and insomnia were reported 2-fold higher in the SEPO group compared to the roxadustat group.

[0320] For the adverse events of special interest (AESI)-deep vein thrombosis (DVT) and pulmonary embolism (PE), there were two subjects (pulmonary embolism, venous thrombosis limb) in the roxadustat arm, and one (deep vein thrombosis) in the SEPO arm.

[0321] The proportion of patients with TEAEs leading to death was numerically higher in the roxadustat group compared with the SEPO group (11.1% vs. 2.7%). All fatal events were assessed as Not Related to the study drug. Some cases were confounded. Patient exposure years (PEY) was about 31% higher for roxadustat compared to SEPO which may have affected event ascertainment. Overall, on-study adverse events were similar with what was seen in TEAEs.

Claims

CLAIMSWhat is claimed is:

1. Use of roxadustat in the manufacture of a medicament for treating chemotherapy- induced anemia in a subject receiving multi-cycle platinum or non-platinum myelosuppressive chemotherapy for a non-myeloid malignancy, wherein the subject has a hemoglobin level <100 g / L prior to treatment and the subject’s blood hemoglobin level decreased at least 10 g / L after the initiation of chemotherapy.

2. The use of claim 1 , wherein the subject has a serum erythropoietin (Epo) level >200 U / L prior to treatment.

3. The use of claim 1 or 2, wherein the subject has an estimated glomerular filtration rate (eGFR) >60 mL / min / 1.73m2prior to treatment.

4. The use of any one of claims 1 to 3, wherein the subject has a transferrin saturation (TSAT) >20% and ferritin >100 ng / mL prior to treatment.

5. The use of any one of claims 1 to 4, wherein the subject has C-reactive protein (CRP) level < ULN (upper limit of normal) prior to treatment.

6. The use of any one of claims 1 to 5, wherein the subject is receiving multi-cycle platinum myelosuppressive chemotherapy.

7. The use of any one of claims 1 to 5, wherein the subject is receiving multi-cycle nonplatinum myelosuppressive chemotherapy.

8. The use of any one of claims 1 to 5, wherein the myelosuppressive chemotherapy is selected from the group consisting of abemaciclib, astragalus mongholicus root, atezolizumab, bevacizumab, calcium folinate, calcium levofolinate, camrelizumab, capecitabine, carboplatin, catequentinib, catequentinib hydrochloride, cetuximab, cisplatin, cyclophosphamide, denosumab, disodium cantharidinate, docetaxel, durvalumab, eleutherococcus senticosus root with rhizome, endostatin, envafolimab, epirubicin hydrochloride, eribulin, eribulin mesilate, etoposide, fluorouracil, fulvestrant, gefitinib, gemcitabine, gemcitabine hydrochloride, gimeracil , inetetamab, irinotecan, irinotecan hydrochloride, liposomal doxorubicin, lobaplatin, mylabris spp., nedaplatin, oteracil potassium, oxaliplatin, paclitaxel, paclitaxel liposome, paclitaxel nanoparticle albuminbound, panax ginseng root, pegaspargase, pembrolizumab, pemetrexed, pemetrexed disodium, pemetrexed disodium heptahydrate, penpulimab, pyridoxine hydrochloride,pyrotinib maleate, rivoceranib mesylate, sintilimab, tamoxifen, tegafur, tislelizumab, toripalimab, and vinorelbine tartrate.

9. The use of any one of claims 1 to 8, wherein the non-myeloid malignancy is selected from the group consisting of breast cancer, lung cancer, gastrointestinal cancers, gynecological cancers, pancreatic cancer, and head and neck cancers.

10. The use of any one of claims 1 to 8, wherein the non-myeloid malignancy is selected from the group consisting of adenocarcinoma gastric, adenocarcinoma of the cervix, adenolymphoma, angiocentric lymphoma, bile duct cancer, bladder transitional cell carcinoma, breast cancer, cervix carcinoma, colon cancer, diffuse large B-cell lymphoma, endometrial cancer, gastric cancer, hepatobiliary cancer, invasive breast carcinoma, invasive ductal breast carcinoma, keratinizing squamous cell carcinoma of nasopharynx, lung adenocarcinoma, lung adenocarcinoma stage IV, lung neoplasm malignant, lung squamous cell carcinoma stage IV, mesothelioma malignant, metastases to abdominal cavity, metastases to adrenals, metastases to bone, metastases to central nervous system, metastases to chest wall, metastases to heart, metastases to liver, metastases to lung, metastases to lymph nodes, metastases to pancreas, metastases to pelvis, metastases to peritoneum, metastases to pharynx, metastases to pleura, metastases to spine, metastases to spleen, nasopharyngeal cancer, neuroendocrine tumor of the lung, esophageal carcinoma, esophageal squamous cell carcinoma, pancreatic carcinoma, ovarian cancer, ovarian cancer stage III, papillary thyroid cancer, peritoneal mesothelioma malignant rectal cancer, sarcomatoid carcinoma of the lung, small cell lung cancer, squamous cell carcinoma of lung, squamous cell carcinoma of the tongue, throat cancer, and uterine cancer.

11. The use of any one of claims 1 to 10, wherein the subject is receiving chemotherapy for at least 8 weeks after the beginning of treatment.

12. The use of any one of claims 1 to 11, wherein the subject is >18 years old prior to treatment.

13. The use of any one of claims 1 to 12, wherein the subject weighs >40 kg prior to treatment.

14. The use of any one of claims 1 to 13, wherein the subject has Eastern Cooperative Oncology Group performance status (ECOG PS) of 0, 1, or 2 prior to treatment.

15. The use of any one of claims 1 to 14, wherein the subject has a life expectancy of >6 months at the beginning of treatment.

16. The use of any one of claims 1 to 15, wherein the roxadustat is crystalline Form A characterized by an X-ray powder diffraction pattern comprising peaks at 8.5, 12.8, 16.2, 21.6, 22.9, and 27.4° 29±0.2° 29.

17. The use of any one of claims 1 to 16, wherein the roxadustat is a solid having a unimodal particle size distribution of D90 of 21 pm to 29 pm, a D50 of 12 pm to 17 pm, and a DIO of 6 pm to 10 pm.

18. The use of any one of claims 1 to 17, wherein the medicament is formulated for oral administration.

19. The use of any one of claims 1 to 18, wherein the medicament further comprises a pharmaceutically acceptable excipient.

20. The use of any one of claims 1 to 19, wherein the medicament is formulated in a capsule.

21. The use of claim 20, wherein the capsule comprises 20 mg of roxadustat.

22. The use of claim 20, wherein the capsule comprises 50 mg of roxadustat.

23. The use of claim 20, wherein the capsule comprises a capsule fill and a capsule shell, wherein the capsule fill comprises 20 mg of roxadustat and pharmaceutically acceptable excipients comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the capsule shell is a gelatin shell comprising titanium dioxide, iron oxide yellow, and gelatin.

24. The use of claim 20, wherein the medicament is formulated in a capsule wherein said capsule comprises a capsule fill and a capsule shell; wherein the capsule fill comprises 20 mg of roxadustat, 101.84 mg of lactose monohydrate 310, 9.36 mg of microcrystalline cellulose PH101, 6.48 mg of povidone K30, 5.76 mg of croscarmellose sodium, and 0.56 mg of magnesium stearate; and the capsule shell is a gelatin shell comprising titanium dioxide, iron oxide yellow, and gelatin, wherein the titanium dioxide is 1%, by weight of the capsule shell and the iron oxide yellow is 2% by weight of the capsule shell.

25. The use of claim 20, wherein the capsule comprises a capsule fill and a capsule shell, wherein the capsule fill comprises 50 mg of roxadustat and pharmaceutically acceptable excipients comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the capsule shell is a gelatin shell comprising Allura red AC, titanium dioxide, iron oxide yellow, and gelatin.

26. The use of claim 20, wherein the medicament is formulated in a capsule wherein said capsule comprises a capsule fill and a capsule shell; wherein the capsule fill comprises 50 mg of roxadustat, 254.6 mg of lactose monohydrate (310), 23.4 mg of microcrystalline cellulose PH101, 16.20 mg of povidone K30, 14.40 mg of croscarmellose sodium, and 1.4 mg of magnesium stearate; and the capsule shell is a gelatin shell comprising Allura red AC, titanium dioxide, iron oxide yellow, and gelatin, wherein the Allura red AC is 1 % by weight of the capsule shell, the titanium dioxide is 1%, by weight of the capsule shell and the iron oxide yellow is 1% by weight of the capsule shell.

27. The use of any one of claims 1 to 19, wherein the medicament is formulated in a tablet.

28. The use of claim 27, wherein the tablet comprises 20 mg of roxadustat.

29. The use of claim 27, wherein the tablet comprises 50 mg of roxadustat.

30. The use of claim 27, wherein the tablet comprises 70 mg of roxadustat.

31. The use of claim 27, wherein the tablet comprises 100 mg of roxadustat.

32. The use of claim 27, wherein the tablet comprises 150 mg of roxadustat.

33. The use of claim 27, wherein the tablet comprises a tablet core and a coating wherein the tablet core comprises 20 mg of roxadustat and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin.

34. The use of claim 33, wherein the tablet comprises a tablet core and a coating wherein the tablet core comprises 42.6 mg of lactose monohydrate, 9.12 mg of microcrystalline cellulose, 3.6 mg of povidone K30, 4.0 mg of croscarmellose sodium and 0.68 mg of magnesium stearate and the coating comprises 2.64 mg poly vinyl alcohol, 1.20 mg talc, 0.74 mg macrogol 3350, 0.28 mg titanium dioxide, 0.58 mg Allura Red AC in aluminum lake 38- 42%, 0.34 mg Allura Red AC in aluminum lake 15-17% and 0.21 mg lecithin.

35. The use of claim 27, wherein the tablet comprises a tablet core and a coating wherein the tablet core comprises 50 mg of roxadustat according to any embodiment described herein and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminumlake, titanium dioxide and lecithin.

36. The use of claim 35, wherein the tablet comprises a tablet core and a coating wherein the tablet core comprises 106.5 mg of lactose monohydrate, 22.8 mg of microcrystalline cellulose, 9.0 mg of povidone K30, 10 mg of croscarmellose sodium and 1.7 mg of magnesium stearate and the coating comprises 4.84 mg poly vinyl alcohol, 2.20 mg talc, 1.36 mg macrogol 3350, 0.51 mg titanium dioxide, 1.07 mg Allura Red AC in aluminum lake 38- 42%, 0.63 mg Allura Red AC in aluminum lake 15-17% and 0.39 mg lecithin.

37. The use of claim 27, wherein the tablet comprises a tablet core and a coating wherein the tablet core comprises 70 mg of roxadustat according to any embodiment described herein and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin.

38. The use of claim 37, wherein the tablet comprises a tablet core and a coating wherein the tablet core comprises 149.1 mg of lactose monohydrate, 31.92 mg of microcrystalline cellulose, 12.6 mg of povidone K30, 14 mg of croscarmellose sodium and 2.38 mg of magnesium stearate and the coating comprises 5.85 mg poly vinyl alcohol, 2.66 mg talc, 1.64 mg macrogol 3350, 0.62 mg titanium dioxide, 1.30 mg Allura Red AC in aluminum lake 38- 42%, 0.76 mg Allura Red AC in aluminum lake 15-17% and 0.47 mg lecithin.

39. The use of claim 27, wherein the tablet comprises a tablet core and a coating wherein the tablet core comprises 100 mg of roxadustat according to any embodiment described herein and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin. In some embodiments, the tablet core comprises lactose monohydrate, microcrystalline cellulose, povidone K30, croscarmellose sodium, and magnesium stearate.

40. The use of claim 39, wherein the tablet comprises a tablet core and a coating wherein the tablet core comprises 213.0 mg of lactose monohydrate, 45.6 mg of microcrystalline cellulose, 18.0 mg of povidone K30, 20 mg of croscarmellose sodium and 3.4 mg of magnesium stearate and the coating comprises 7.92 mg poly vinyl alcohol, 3.6 mg talc, 2.22 mg macrogol 3350, 0.84 mg titanium dioxide, 1.75 mg Allura Red AC in aluminum lake 38-42%, 1.03 mg Allura Red AC in aluminum lake 15-17% and 0.63 mg lecithin.

41. The use of claim 27, wherein the tablet comprises a tablet core and a coating wherein the tablet core comprises 150 mg of roxadustat according to any embodiment described herein and a pharmaceutically acceptable excipient comprising lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate; and the coating comprises poly vinyl alcohol, talc, macrogol 3350, Allura Red AC in aluminum lake, titanium dioxide and lecithin.

42. The use of claim 41, wherein the tablet comprises a tablet core and a coating wherein the tablet core comprises 319.5 mg of lactose monohydrate, 68.4 mg of microcrystalline cellulose, 27.0 mg of povidone K30, 30 mg of croscarmellose sodium and 5.1 mg of magnesium stearate and the coating comprises 10.56 mg poly vinyl alcohol, 4.8 mg talc, 2.96 mg macrogol 3350, 1.12 mg titanium dioxide, 2.34 mg Allura Red AC in aluminum lake 38- 42%, 1.38 mg Allura Red AC in aluminum lake 15-17% and 0.84 mg lecithin.

43. The use of any one of claims 1 to 42, wherein the medicament increases the blood hemoglobin level in the subject following administration compared with the subject’s hemoglobin level prior to administration of the medicament.

44. The use of claim 43, wherein the subject reaches and maintains a hemoglobin level of >100 g / L up to 130 g / L during treatment.

45. The use of claim 43, wherein the blood hemoglobin level in the subject is increased >10 g / L following administration of the medicament, compared with the subject’s hemoglobin level prior to administration of the medicament, provided the blood hemoglobin level does not exceed 130 g / L.

46. The use of claim 43, wherein the blood hemoglobin level in the subject is increased >15 g / L following administration of the medicament, compared with the subject’s hemoglobin level prior to administration of the medicament, provided the blood hemoglobin level does not exceed 130 g / L.

47. The use of claim 43, wherein the blood hemoglobin level in the subject is increased >20 g / L following administration of the medicament compared with the subject’s hemoglobin level prior to administration of the medicament, provided the blood hemoglobin level does not exceed 130 g / L.

48. The use of any one of claims 1 to 47, wherein the medicament is labeled foradministration to the subject based on a dose of roxadustat relative to body weight of the subject.

49. The use of claim 48, wherein the subject has a body weight of 40 to <50 kg and the dose of roxadustat is 50-150 mg, particularly about 100 mg.

50. The use of claim 48, wherein the subject has a body weight of 50 to 60 kg and the dose of roxadustat is 70-200 mg, particularly about 120 mg.

51. The use of claim 48, wherein the subj ect has a body weight of >60 kg and the dose of roxadustat is 100-250 mg, particularly about 150 mg.

52. The use of claim 48, wherein the subject has a body weight of >60 to <80 kg and the dose of roxadustat is 100-200 mg, particularly about 150 mg.

53. The use of claim 48, wherein the subject has a body weight of >80 kg and the dose of roxadustat is 150-250 mg, particularly about 200 mg.

54. The use of claim 48, wherein the dose is about 1 to 4 milligrams of roxadustat per kilogram of the subject’s body weight.

55. The use of claim 48, wherein the dose is about 1 to 3.5 milligrams of roxadustat per kilogram of the subject’s body weight.

56. The use of claim 48, wherein the dose is about 1.5 to 3.5 milligrams of roxadustat per kilogram of the subject’s body weight.

57. The use of claim 48, wherein the dose is about 2.0 to 3.5 milligrams of roxadustat per kilogram of the subject’s body weight.

58. The use of claim 48, wherein the dose is about 2.0 to 2.5 milligrams of roxadustat per kilogram of the subject’s body weight, particularly about 2.15±0.33 mg / kg.

59. The use of any one of claims 1 to 58, wherein the medicament is labeled to administer a dose of roxadustat three times a week.

60. The use of any one of claims 1 to 42, wherein the medicament is labeled for treating anemia in a subject receiving multi-cycle platinum or non-platinum myelosuppressive chemotherapy for a non-myeloid malignancy, wherein the subject has a blood hemoglobin level <100 g / L prior to treatment, and comprises orally administering to the subject 100 mg to 150 mg of roxadustat three times a week, wherein the subject achieves a hemoglobin level of >110 g / L to 130 g / L during treatment.

61. The use of any one of claims 1 to 42, wherein the medicament is labeled for treating anemia in a subject receiving multi-cycle platinum or non-platinum myelosuppressive chemotherapy for a non-myeloid malignancy, wherein the subject has a blood hemoglobin level <100 g / L prior to treatment, and comprises orally administering to the subject 50 mg to 400 mg of roxadustat three times a week, wherein the blood hemoglobin level in the subject is increased following administration of the roxadustat, compared with the subject’s hemoglobin level prior to administration of the roxadustat provided the blood hemoglobin level does not exceed 130 g / L; provided the roxadustat is administered at least 2 days apart and no more than 4 days apart; and provided that if the subject is receiving paclitaxel as part of the myelosuppressive chemotherapy, roxadustat dosing is held for 24 hours before or after the subject receives the paclitaxel.

62. The use of any one of claims 1 to 42, wherein the medicament is labeled for treating anemia in a subject receiving multi-cycle platinum or non-platinum myelosuppressive chemotherapy for a non-myeloid malignancy, wherein the subject has a blood hemoglobin level <100 g / L prior to treatment, and comprises orally administering to the subject 2.0 to 3.5 milligrams of roxadustat per kilogram of the subject’s body weight three times a week, wherein the blood hemoglobin level in the subject is increased following administration of the roxadustat, compared with the subject’s hemoglobin level prior to administration of the roxadustat, provided the blood hemoglobin level does not exceed 130 g / L; provided the roxadustat is administered at least 2 days apart and no more than 4 days apart; provided the dose does not exceed 400 mg; and provided that if the subject is receiving paclitaxel as part of the myelosuppressive chemotherapy, roxadustat dosing is held for 24 hours before or after the subject receives the paclitaxel.

63. The use of any one of claims 1 to 62, wherein the medicament is further labeled to optionally increase or decrease the dose of roxadustat until the subject achieves and maintains a blood hemoglobin level of 100 to 120 g / L, providing the dose does not exceed 400 mg.

64. The use of claim 63, wherein the increasing or decreasing the dose of roxadustat results in a dose of 50 mg, 70 mg, 100 mg, 120 mg, 150 mg, 200 mg, 250 mg, 300 mg, or 400 mg.

Citation Information

Patent Citations

  • Compounds and methods for treatment of chemotherapy-induced anemia

    US20070292433A1

  • New crystal form of roxadustat and preparation method thereof

    WO2020135058A1

  • Compounds and composition for the treatment of anemia

    WO2022150623A1